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ABSTRACT 
Activation and proliferation of antigen-specific T cells is the hallmark of an 
anti-viral immune response. Effector T cells generated during an immune 
response are heterogeneous in regards to their ability to populate the memory 
pool once the immune response has resolved. Initial T cell activation takes place 
in the lymphoid organs, after which T cells migrate into the non-lymphoid tissues. 
The presence of memory T cells at non-lymphoid tissue sites has been shown to 
be critical for protection against secondary virus challenge. Our lab has 
previously demonstrated that during and after the resolution of the immune 
response to Lymphocytic choriomeningitis virus (LCMV) CD8+T cells in the non-
lymphoid tissues are more resistant to apoptosis than those in the lymphoid 
organs. This stability of T cells in the non-lymphoid tissues may be critical in 
ensuring protection against a secondary virus challenge. 
 Mechanisms regulating tissue-dependent differences in CD8+T cell 
apoptosis were studied in an acute LCMV infection model. Virus-specific CD8+T 
cells from lymphoid (spleen, mesenteric lymph nodes (MLN), inguinal lymph 
nodes (ILN)) and non-lymphoid tissues (peritoneal exudate cells (PEC), fat-pads) 
were compared for expression of surface antigenic markers known to correlate 
with a memory phenotype. Non-lymphoid tissues were enriched in IL-7Rhi, 
KLRG-1lo, CD27hi and CXCR3hi virus-specific CD8+ T cells, and the presence of 
these antigenic markers correlated with increased memory potential and survival. 
Transcription factors in addition to cell surface antigens were assessed as 
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correlates of resistance to apoptosis. Virus-specific CD8+T cells in the non-
lymphoid tissues were enriched in cells expressing T cell factor-1 (TCF-1), which 
correlated with increased memory potential and survival. CD8+T cells in the 
peritoneum of TCF-1-deficient mice had decreased survival during resolution of 
the immune response to LCMV, suggesting a role for TCF-1 in promoting survival 
in the non-lymphoid tissues. 
As an additional mechanism, I investigated whether apoptosis-resistant 
CD8+T cells migrate to non-lymphoid tissues and contribute to tissue-dependent 
apoptotic differences. CXCR3+ CD8+T cells resisted apoptosis and accumulated 
in the lymph nodes of mice treated with FTY720, which blocks the export of 
lymph node cells into the peripheral tissues. The PECs expressed increased 
amounts of CXCR3 ligands, CXCL9 and CXCL10, which may have recruited the 
non-apoptotic cells from the lymph nodes. By adoptively transferring splenic T 
cells into the spleen or PEC environment I showed that the peritoneal 
environment through a yet undefined factor promoted survival of CD8+T cells. In 
this study I have elucidated the mechanisms by which CD8+T cells preferentially 
survive in the non-lymphoid tissues. I found that non-lymphoid tissues were 
enriched in memory-phenotype CD8+T cells which were intrinsically resistant to 
apoptosis irrespective of the tissue environment. Furthermore, apoptosis-
resistant CD8+T cells may preferentially migrate into the non-lymphoid tissues 
where the availability of tissue-specific factors may enhance memory cell 
survival. 
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Few transcription factors have been identified that regulate CD8+T cell 
effector-memory differentiation during an immune response. In this thesis, I have 
also studied the mechanism by which the transcription factor Blimp-1 regulates 
the generation of effector and memory CD8+T cells. Blimp-1 is known to repress 
a large number of target genes, and ChIP (chromatin immunoprecipitation) 
sequencing analysis done by Dr. HyunMu Shin in the lab of Dr. Leslie J. Berg 
identified CD25 (IL-2Rα) and CD27 as potential targets of Blimp-1. I found that 
Blimp-1-deficient CD8+T cells had sustained expression of CD25 (IL-2Rα) and 
CD27 during peak and resolution of the immune response to LCMV. By 
performing adoptive transfers of CD25hi and CD27hi CD8+T cells I showed that 
CD25 and CD27 expression on CD8+T cells during resolution of the immune 
response correlates with enhanced survival. Silencing Il2rα and Cd27 expression 
reduced the Blimp-1-deficient CD8+T cell response, suggesting that sustained 
expression of CD25 and CD27 was in part responsible for the enhanced CD8+T 
cell response seen in the Blimp-1-deficient mice. Furthermore, our collaborator 
Dr. HyunMu Shin showed that CD25 and CD27 are direct targets of Blimp-1, and 
that Blimp-1 recruits histone modifying enzymes to Il2rα and Cd27 loci to 
suppress their expression during the peak of the anti-viral immune response. 
This study identifies one of the mechanisms by which Blimp-1 regulates the 
balance between generation of effector and memory CD8+T cells. 
In this thesis work I also studied the function of the transcription factor 
ROG (Repressor of GATA-3) in regulating in vivo T cell responses during both 
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acute and chronic LCMV infection. ROG-deficient mice had increased CD8+T cell 
responses during an acute LCMV infection. ROG deficiency also led to the 
generation of memory T cells with an enhanced recall response compared to WT 
controls. By using LCMV-specific P14+ TCR transgenic ROG-deficient CD8+T 
cells these defects were shown to be T cell intrinsic. ROG-deficient mice had 
enhanced CD8+T cell responses and viral clearance during a persistent high 
dose LCMV Clone 13 infection. During chronic LCMV infection ROG-deficient 
mice also had increased lung pathology and mortality. The results indicate that 
ROG negatively regulates T cell responses and memory generation during both 
acute and chronic LCMV infection. 
The studies highlighted in this thesis elucidate the mechanisms promoting 
CD8+T cell survival in non-lymphoid tissues as well as transcription factor-
mediated regulation of memory CD8+T cell differentiation. Knowledge of this will 
help us better understand T cell immunity after infections and may eventually 
help develop better vaccines.  
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CHAPTER I: INTRODUCTION 
A. LCMV 
LCMV is an old world Arenavirus with Mus musculus being its natural 
host. Studies with the LCMV infection model system in mice have contributed 
extensively to our knowledge of immune tolerance, MHC restriction, T cell 
exhaustion, T cell memory, and NK cell activation and specificity (1, 2). Nobel 
Prize winning studies by Burnet and Fenner on immunological tolerance and 
Zinkernagel and Doherty on T cell recognition of immune infected cells were 
done using the LCMV infection model (1). 
Originally LCMV was isolated by Charles Armstrong in 1933 while 
studying epidemic encephalitis in St.Louis, MO (2). Subsequently other LCMV 
stains were independently isolated, and the most commonly used LCMV strains 
in the laboratory include Armstrong, Clone 13, Traub, and WE. In mice a low to 
medium inoculum of LCMV causes an acute infection which is cleared by a 
strong cytotoxic T lymphocyte (CTL) response. Intracranial infection in mice 
leads to severe acute meningoencephalitis and in utero infection within 24 hours 
of birth leads to a persistent life-long infection in mice (3). LCMV can be 
transmitted to humans by direct contact or by inhalation of infected rodent 
excreta and can cause subclinical infection or moderate to severe meningitis. 
LCMV has also been known to cause birth defects or spontaneous abortion of 
the human fetus (4). 
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LCMV particles are pleomorphic in appearance and are roughly spherical 
with spiked projections formed by the envelope glycoproteins (5). LCMV is an 
ambisense enveloped RNA virus which encodes four genes from two RNAs (6). 
The large 31S L RNA codes for two proteins, the L protein which is the RNA 
dependent RNA polymerase and the small zinc-binding Z protein. The short 23S 
RNA encodes for nucleoprotein (NP) and glycoprotein (GP). The glycoprotein is 
further cleaved to form the GP1 (integral membrane protein) and GP2 (peripheral 
membrane protein) (6). GP are trimeric Class-I fusion proteins wherein GP-1 
functions as receptor binding and GP-2 functions as fusion mediating protein (7). 
The glycosylated peripheral plasma membrane protein α-dystroglycan has been 
identified as the host cellular receptor for LCMV and some other arenavirus 
members (8). Entry into the host cell is mediated through large smooth walled 
vesicles followed by pH mediated fusion (9). Recently, it was shown that LCMV 
can use clathrin-independent late endosomes for entry into the host cells (10). 
Viral replication occurs in the cytoplasm after which LCMV buds from the plasma 
membrane. 
LCMV-variant Clone 13 has been widely used to study T cell responses 
during persistent infection (11). The strain was originally identified in spleens of 
LCMV Armstrong infected adult carrier mice (12). Clone 13 differs from the parent 
Armstrong strain due to a single amino acid change in the polymerase (lysine to 
glutamine at amino acid 1079) and glycoprotein GP-1 (phenylalanine to leucine 
at 260 position) (13). The mutation in the GP-1 of Clone 13 variant leads to higher 
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affinity of the viral glycoprotein for α-dystroglycan expressed on macrophages 
and CD11c+ and DEC-205+ dendritic cells (14, 15). LCMV Clone 13 has increased 
growth in the lymphoid tissues and can systemically spread and replicate in both 
lymphoid and non-lymphoid tissues to cause persistent infection (13) as opposed 
to the parent Armstrong strain which replicates in lymphoid tissues and fails to 
cause T cell exhaustion (11). For most of my studies in this thesis I have used 
LCMV Armstrong, and in Chapter V some studies have been performed with 
LCMV Clone 13 strain. 
B. Immune response to LCMV 
The LCMV model system has contributed immensely to our knowledge of 
T cell responses to viral infection. Low to moderate inoculum of LCMV via 
intraperitoneal (i.p) or intravenous (i.v) route induces a strong CTL response 
leading to viral clearance and development of T cell memory to LCMV (Figure I-
1). LCMV is a strong type I IFN (Interferon) inducer, and unlike some other 
viruses, LCMV does not modulate host Class I MHC expression (16), thereby 
leading to induction of a strong CTL response and sterilizing immunity. 
Early responses to viral replication are characterized by induction of type I 
IFN α/β, the levels of which peak around day 2 post infection (17). Type I IFN is 
important for regulating early viral load, as mice deficient in type-I IFN receptor 
had a reduced CTL response to LCMV, and had increased viral loads leading to 
a persistent infection (18, 19). Type I IFNs are also important for induction of NK 
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(Natural killer) cell activation and proliferation during early stages of the immune 
response (17). Viral load in NK depleted mice was found to be similar to control 
animals, suggesting that NK cells do not play a role in regulating the response to 
acute LCMV infection (20). However, IFNγ production by NK cells has been 
shown to reduce viral burden at the site of peripheral inoculation (21). In addition, 
NK cells have been shown to be important in regulating T cell responses during 
persistent LCMV infection (22). 
Viral antigens presented in the context of Class-I MHC by antigen-
presenting cells (APC) lead to activation and proliferation of CD8+T cells. As 
shown in Figure I-1 CD8+T cell responses can be divided into three phases: a) 
activation and proliferation of CD8+T cells, b) silencing of immune response by 
CD8+T cell apoptosis on clearance of viral antigen, and c) generation of memory 
CD8+T cells, which provide long lasting immunity to secondary challenge. CD8+T 
cell apoptosis and memory generation has been covered in greater details in 
later sections. 
During early stages of LCMV infection activated T cells undergo attrition, 
and this attrition is dependent on type I IFN and the pro-apoptotic molecule Bim 
(23-25). T cell numbers increase by day 6 post infection and reach a peak around 
day 8 or 9. At the peak of the immune response CD8+T cell numbers increase 5-
20 fold in the spleen as compared to a naïve mouse (26). CD8+T cells express 
several markers which allow detection of activated T cells (CD44hi, CD11ahi, 
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CD11bhi, VLA-4hi, CD62Llo, IL-7Rlo, KLRG-1hi), but recent studies have shown 
that there is considerable heterogeneity in the surface antigen expression of the 
activated T cell pool (27), allowing for detection of cells that might preferentially 
survive to become memory T cells. 
The immune response to LCMV is mainly a Th1 type response with CD4+ 
and CD8+T cells producing high amounts of IFNγ and IL-2. CTL kill LCMV-
infected target cells by direct contact and secrete perforins and granzymes. 
Perforin-mediated killing seems to be the major cytotoxic mechanism, as perforin 
deficient mice develop a CTL response but do not clear the virus (28). IFNγ-
mediated killing of targets may also be a cytotoxic mechanism,  as mice deficient 
in IFNγ receptor or depleted of IFNγ by antibody had increased LCMV titers (29, 
30). 
CD4+T cells are activated and proliferate in response to LCMV infection, 
and approximately 10% of CD4+T cells can be shown to be virus-specific at the 
peak of the response (26). CD4+T cells do not seem to regulate acute LCMV 
infection, as mice lacking CD4+T cells (due to CD4 deficiency or CD4 antibody 
depletion) have a functional CD8+T cell response and clear the virus (31-33). 
However, survival and maintenance of functional CD8+T cell memory requires 
CD4+T cells, as CD8+T cells generated in absence of CD4+T cells are 
progressively lost and mount a defective secondary response (34-36). Humoral 
responses also develop in the host against LCMV nucleoprotein and 
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glycoproteins, and IFNγ induced IgG2a isotype is the predominant response (1). 
CD8+T cell responses are normal in B cell-deficient or B cell-depleted mice, 
suggesting against a role of B cells in LCMV immunity (37, 38). However, as seen 
for CD4+ T cells, B cells have been shown to be important for CD8+T cell memory 
generation and long term viral control (39, 40). 
C.  T cell apoptosis and silencing of the immune response 
Upon clearance of the viral antigen silencing of the immune response 
takes place to restore homeostasis in the T lymphocyte compartment. Most of 
the virus-specific CD8+T cells die by apoptosis (41), and it is estimated that 
approximately 90-95% of effector T cells are eliminated in the process (42). 
Apoptosis is a form of programmed cell death, which is characterized by 
typical morphological changes that include membrane blebbing, DNA 
fragmentation and degradation of cellular components without the loss of 
membrane integrity. This form of cell death is advantageous, as apoptotic cells 
are rapidly cleared by macrophages and other phagocytes without inducing 
inflammation or an immune response. Depending on the upstream signals 
apoptosis can be initiated by one of the two pathways: a) extrinsic pathway or b) 
intrinsic pathway (42-44). 
Induction of the extrinsic cell death pathway requires signals from soluble 
ligands and/or other cells. The signals for cell death are initiated at the cell 
surface by binding of death receptors belonging to Tumor Necrosis Factor (TNF) 
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superfamily such as TNFR and Fas to their respective ligands (42). The 
aggregation of death receptors at the cell surface initiates downstream signaling, 
leading to recruitment of death-domain containing adaptors such as FADD (Fas 
associated protein with death-domain) or TRADD (Tumor Necrosis Factor 
Receptor Type 1-associated death-domain protein) along with pro Caspase-8. 
Homodimerization and self-cleavage of pro-Caspase 8 releases active Caspase-
8, which activates downstream caspases leading to apoptosis (45). The role of 
extrinsic apoptotic pathway has been evaluated in CD8+T cell contraction. 
Activated T cells when re-stimulated through their TCR undergo cell death via 
Fas and TNFR1 by a mechanism known as activation-induced cell death (AICD) 
(45, 46). IL-2 (Interleukin-2), a T cell growth factor was shown to sensitize T cells 
to AICD by down-regulating apoptotic inhibitor c-FLIP (47). However, CD8+T cells 
undergo contraction during silencing of the immune response in mice deficient in 
TNFR, Fas and FasL (48-50). Thus, the in vivo data suggests that AICD does not 
play a role in CD8+T cell contraction as antigen is no longer present. AICD and 
extrinsic cell death pathway might be more relevant to a persistent infection 
setting or autoimmunity where the antigen will be chronically present to trigger 
the TCR.  
The intrinsic cell death pathway is induced upon signals of cellular stress 
and damage. The balance between pro- and anti-apoptotic members of the Bcl-2 
family of proteins are known to regulate the intrinsic pathway of apoptosis 
(51).The anti-apoptotic members of the Bcl-2 family include: Bcl-2, Bcl-xl, Mcl-1, 
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A1 which are known to inhibit the function of pro-apoptotic members. Some of 
the pro-apoptotic members include Bax, Bak, Bim, Bad and Bid. The members of 
the Bcl-2 family share at least one Bcl-2 homology domain (BH). Under 
conditions of stress anti-apoptotic members of the Bcl-2 family are antagonized 
to initiate a cascade of events leading to mitochondrial depolarization, release of 
cytochrome c and activation of Caspase-9, which then activates downstream 
effector caspases to induce apoptosis (51). During silencing of the immune 
response the antigen is no longer present and growth or survival factors become 
limited. Therefore it is thought that CD8+T cell contraction occurs due to cytokine 
deprivation (52) leading to induction of the intrinsic apoptotic pathways. Bcl-2 is 
expressed in naïve T cells, down-regulated in effector T cells and surviving 
memory T cells express high levels of Bcl-2 (53). Bcl-2 transgene-expressing T 
cells are protected from IL-2 deprivation induced apoptosis, though CD8+T cell 
contraction was not blocked in Bcl-2 overexpressing mice (50). Higher levels of 
the anti-apoptotic Bcl-2 in effector CD8+T cells have been shown to be important 
in counteracting the effects of pro-apoptotic Bim, thereby allowing for survival of 
cells during contraction of the immune response (54). Further supporting the role 
of intrinsic cell death pathway in silencing of the immune response, Bim deficient 
T cells were resistant to cytokine withdrawal induced apoptosis, and Bim was 
necessary for T cell death during resolution of the immune response to Herpes 
simplex virus (HSV) infection (55, 56). Mice deficient in both Bim and Fas had a 
lymph node-specific block in contraction of the LCMV-specific immune response 
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(57). Overall, this suggests that the cytokine withdrawal induced intrinsic cell 
death pathway plays a major role in T cell death during silencing of the immune 
response, but, under certain infection conditions and at certain tissue sites both 
intrinsic and extrinsic pathways may act concurrently to regulate silencing of the 
immune response. 
Caspases are cystinyl-aspartate-requiring proteinases that are 
synthesized as inactive zymogens which release the active form upon proteolytic 
cleavage (58). Caspases can be divided into initiator caspases (Caspase-2,-8,-9,-
10), which interact with upstream adaptor molecules, or executioner caspases 
(Caspase-3,-6,-7), which cleave various cellular substrates to induce apoptosis 
(59). The extrinsic and intrinsic cell death pathways converge to activate 
downstream executioner caspases. Levels of activated Caspase-3 increase in 
effector T cells, directly correlating with their sensitivity to apoptotic stimuli (60), 
and T cells from Caspase-3-deficient mice have reduced susceptibility to 
activation-induced cell death (AICD) driven by CD3 crosslinking and Fas ligands 
(61). Therefore, assays to detect active-Caspases have been reliably used to 
identify apoptotic cells. 
Large numbers of assays are available to identify apoptotic cells. During 
the early stages of apoptosis phosphatidylserine residues externalize to outer 
leaflet of the plasma membrane, marking the cells for phagocytic uptake. 
Annexin V is a Ca2+-dependent phospholipid-binding protein and has high affinity 
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for phosphatidylserine. Fluorescent-conjugate-labeled Annexin V can be used to 
identify pre-apoptotic cells via flocytometry or fluorescent microscopy (62). Since 
Annexin V can bind to phosphatidylserine expressed on the surface of necrotic 
cells, this assay is usually performed along with nucleic acid stains such as 
7AAD (7-aminoactinomycin D) to identify pre-apoptotic cells which have not lost 
their membrane integrity. Though Annexin V has been shown to bind to activated 
and proliferating cells (63, 64), Annexin V staining is still a reliable assay to identify 
pre-apoptotic cells (64). Moreover, our lab has shown that sorted and adoptively 
transferred Annexin V+ T cells do not develop into functional memory (65), 
confirming the reliability of this assay. End stage apoptotic cells undergo DNA 
fragmentation, and this can be visualized using the TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) assay. Terminal 
transferase is used to add fluorescent-labeled UTP to the 3’ end of DNA 
fragments which can be visualized by flocytometry or fluorescent microscopy (66). 
In this thesis I have used Annexin V, TUNEL and active Caspase-3 
staining assays to identify apoptotic cells. Wherever possible multiple assays 
have been used to reliably confirm the presence of apoptotic cells. 
D. Generation of CD8+T cell memory 
Upon clearance of the viral antigen most of the virus-specific CD8+T cells 
die by apoptosis, leaving behind a small (5-10% of the peak response) but stable 
population of memory CD8+T cells to provide protection to secondary challenge. 
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The initial TCR engagement triggers the up-regulation of co-stimulatory 
molecules and cytokine receptors, which are critical for the clonal expansion, 
survival and memory generation of the responding CD8+ T cells (67). 
Heterogeneous populations of effector CD8+T cells are generated during an 
immune response, and various models have been proposed to explain CD8+T 
cell differentiation into effector and memory populations (68). Terminally 
differentiated effector CD8+T cells, which are destined to die, can be 
distinguished from memory precursor CD8+T cells based on expression of 
surface markers and transcription factors (Figure I-2) (68, 69), which characterize 
their activation state and highlight their conversion into memory. 
IL-2, IL-7 and IL-15 belong to the common γ chain family of cytokines and 
are required at various stages for an optimal T cell immune response. IL-7 and 
IL-15 are known to mediate survival and self-renewal of memory CD8+T cell 
populations (70, 71). CD8+T cells expressing IL-7Rα preferentially give rise to 
memory CD8+T cells (72), but IL-7Rα expression is necessary but not sufficient 
for CD8+T cell memory formation (73). Surface expression of IL-7Rα along with 
KLRG-1 (inhibitory receptor found on T and NK cells) has been used to identify  
cells which will preferentially make it into memory (Memory Precursor effector 
cells: IL-7Rhi KLRG-1lo) or die during contraction of the immune response (Short-
Lived effector cells: IL-7Rlo KLRG-1hi) (69, 74). IL-2 is a T cell growth factor and 
plays an important role in regulating CD8+ T cell responses during the different 
stages of viral infection (75). In vivo administration of IL-2 during expansion phase  
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of the viral response is detrimental to the survival of CD8+T cells; however, IL-2 
therapy during the contraction and memory stages of the response promotes 
CD8+T cell survival (76). Additional studies have indicated that both primary and 
secondary CD8+T cell responses are impaired in the absence of IL-2 receptor 
signaling (77, 78). Moreover, IL-2-producing CD8+T cells are more likely to 
become memory cells than those that do not make IL-2 (79). CD25, a subunit of 
the IL-2 receptor is up-regulated by IL-2 in conjunction with TCR stimulation (75), 
and at early stages of the response to LCMV infection, CD25 expression 
promotes the development of terminally-differentiated effector CD8+T cells (80). 
We have recently shown that following the peak of the CD8+T cell response to 
LCMV, higher expression of CD25 correlates with enhanced survival and/or 
persistence of virus-specific CD8+T cells (81). 
Apart from cytokine receptors, various co-stimulatory and chemokine 
receptors have been shown to be important in generation of memory CD8+T 
cells. CD27 is a co-stimulatory receptor of the TNFR family and has also been 
used as a marker to identify memory precursor CD8+T cells (27). Expression of 
CD27 on virus-specific CD8+T cells promotes survival, induces IL-7R expression, 
and protects against Fas-dependent apoptosis (82-84). CD27-CD70 interactions 
have been shown to induce autocrine IL-2 production in CD8+T cells, thereby 
promoting their survival (85). Activated T cells may express CXCR3, a chemokine 
receptor required for T cell chemotaxis to the site of antigen (86, 87). Moreover, 
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expression of IL-7R, CD27 and CXCR3 has been used to identify memory CD8+T 
cell populations with an efficient recall response (88). 
Transcriptional regulation of effector and memory CD8+T cell 
differentiation is beginning to be elucidated. Transcriptional profiling of effector 
and memory CD8+ T cells in both acute and chronic virus infection models has 
recently provided insight into the gene expression programs characterizing 
distinct cell subsets (89).   
Blimp-1 (B lymphocyte induced maturation protein-1, encoded by Prdm1) 
is a transcription factor important for regulating differentiation of various cell types 
(90). Blimp-1 is expressed at high levels in terminally differentiated CD8+T cells 
and can be induced by IL-2, IL-12 and IL-21 (80, 91-93). Blimp-1 suppresses 
memory generation and Blimp-1-deficient CD8+T cells are better at producing IL-
2 and develop into CD62Lhi IL-7Rαhi memory precursor effector CD8+T cells (94, 
95). In an Influenza infection model Blimp-1 was shown to be important for 
recruitment of effector CD8+T cells to the lung (95). Blimp-1 is also expressed in 
exhausted CD8+T cells, which express inhibitory receptors during chronic LCMV 
infection (96). One recent study shows that Blimp-1 negatively regulates 
expression of the DNA-binding inhibitor Id3, thereby contributing to the 
development of short-lived effector T cells (97). Bcl-6 is a transcription factor 
expressed in memory T cells and is an antagonist of Blimp-1 activity (94, 98). Bcl-
6 has been shown to be important for generation and maintenance of memory 
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CD8+T cells (99, 100). ChIP-sequencing analysis done by Dr. HyunMu Shin also 
identified Bcl-6 as a potential direct target of Blimp-1 in activated CD8+T cells 
(81). 
T cell factor-1 (TCF-1, encoded by Tcf7) and lymphoid enhancer-binding 
factor-1 (LEF-1, encoded by Lef1) are  transcription factors acting downstream in 
the Wnt signaling pathway (101). TCF-1 and LEF-1 have redundant roles in 
promoting thymocyte maturation (102). Apart from its role in thymocyte  
differentiation (103), TCF-1 was shown to be important for generation and 
maintenance of memory CD8+T cells (104, 105), and TCF-1 deficient CD8+T cells 
had impaired expansion after a secondary antigen challenge (104-106). Memory 
CD8+T cells were progressively lost due to  TCF-1 deficiency, which was 
associated with decreased expression of the transcription factor EOMES and the 
loss of IL-15 driven proliferation (105). Loss of TCF-1 and LEF-1 in CD8+T cells 
was shown to completely abrogate development of memory precursor effector 
cells (107).  
            T-bet and EOMES are T-box transcription factors which can also regulate 
effector and memory CD8+T cell generation. T-bet and EOMES co-operate to 
induce CD122 (IL-2Rβ) expression and IL-15 responsiveness in CD8+T cells 
(108). However, T-bet and EOMES have antagonistic roles in generation and 
maintenance of memory CD8+T cells. T-bet promotes the generation of terminally 
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differentiated effector cells (108, 109), whereas EOMES expression promotes 
generation of memory precursor effector CD8+T cells (110). 
The forkhead box (Fox) family of transcription factors have been show to 
play a role regulating T cell homeostasis and tolerance (111). FoxO1 has been 
shown to be important for generation of competent memory T cells. Primary 
CD8+T cell responses to Listeria and LCMV were normal in mice lacking FoxO1 
in CD8+T cells (112, 113). However, loss of FoxO1 decreased the generation of 
MPEC, and memory T cells were lost over time primarily due to decreased TCF-
1 and CCR7 expression (112, 113). FoxO3a also belongs to the Fox family of 
transcription factors and was shown to negatively impact CD8+T cell memory 
formation by promoting contraction of CD8+T cells during resolution of immune 
response to Listeria infection (114). 
Transcription factors of the JAK (Janus kinases) - STAT (Signal 
transducers and activators of transcription) family of transcription factors transmit 
signals from cell surface receptors to in response to a large number of growth 
factors and cytokines (115). Once activated in response to extracellular signals 
STAT proteins dimerize and translocate to nucleus to trans-activate a number of 
target genes. STAT proteins are known to play a key role in CTL differentiation in 
response to extracellular cytokine signals (68). STAT4 is induced downstream of 
pro-inflammatory cytokines IL-12 and type I IFN signaling (98, 116). At the peak of 
the immune response to acute LCMV infection STAT4 deficient mice had 
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increased frequency and number of MPEC suggesting that STAT4 negatively 
regulates memory development (117). STAT5 can be induced downstream of γ 
chain family of cytokines such as IL-2, IL-7 and IL-15 (115). STAT5 was shown to 
promote effector and memory T cell survival during acute LCMV infection (118) 
(119). Furthermore, STAT5 was shown to be critical for IL-7 and IL-15 driven 
upregulation of Bcl-2 thereby promoting survival of effector CD8+T cells (118, 119). 
STAT3 can be induced downstream of IL-10 and IL-21 and STAT-3 deficient 
CD8+T cells were defective in generating a memory cell pool (98). In the same 
study STAT-3 was shown to be important for maintenance of EOMES and Bcl-6 
expression, which are transcription factors associated with memory development. 
Overall these studies show that signals induced by cytokines can induce cues to 
the cells to regulate the generation of effector and memory CD8+T cells. 
Recent studies have identified that strength of TCR signals can inscript a 
transcriptional program in effector CD8+T cells governing their fate. In this regard 
IRF4 (Interferon regulatory factor 4) has been shown to play a critical role in 
orchestrating expansion and effector differentiation of CD8+T cells in response to 
TCR signals (120-122). IRF4  was shown to be induced in a dose dependent 
manner depending on the strength of TCR signaling and antigen specific IRF4 
deficient CD8+T cells failed to expand and differentiate during Influenza and 
LCMV immune response (120, 121). Furthermore, IRF4 was shown to directly bind 
to Prdm1 and FoxO1 which are genes known to be  involved in effector T cell 
differentiation and metabolic programming respectively (120, 121). Several studies 
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have also identified an inter-relationship between pathways involved in cellular 
metabolism and T cell differentiation.  mTOR (mammalian target of rapamycin) 
kinases integrate nutrient sensing pathways and coordinate cell metabolism (123). 
Inhibition of the mTOR pathway by rapamycin during acute LCMV infection 
increased the magnitude of LCMV specific CD8+T cell response and led to 
generation of increased proportion of MPEC (124). mTOR activity was shown 
inhibit the transcription factor FoxO1 which led to induction of T-bet and 
suppression of EOMES thereby promoting terminal effector differentiation (125, 
126). Overall these studies show that TCR signals and enzymes involved in 
sensing the metabolism of T cells can also instruct a transcriptional program to 
regulate their differentiation. 
Though we still do not completely understand how memory CD8+T cells 
are generated the studies mentioned above have shown that strength and 
duration of TCR signals, exposure to inflammatory cytokines and co-stimulatory 
molecules instruct a transcriptional program within the T cells governing their fate 
conversion to memory. With the advent of technologies for high throughput 
screening of transcriptional profiles and the availability of vast array of gene 
expression data it has now become possible to define transcriptional networks 
which regulate T cell differentiation during various stages of the immune 
response. A recent study identified key transcriptional signatures and networks 
which can be used to predict memory potential of effector CD8+T cells (127). In 
this study ten core gene clusters and their predicted transcriptional regulators 
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were identified based on their gene expression profiles in OVA-specific CD8+T 
cells during various stages of immune response to Listeria infection. Each gene 
cluster was enriched in genes with a specific biological function during the 
immune response, and by profiling effector and memory T cell populations it was 
shown that expression of these core gene clusters can be used to predict effector 
or memory potential of CD8+T cells. Consistent with previously published results 
Blimp-1, STAT4, ID2, T-bet were identified as regulators of terminal effector 
differentiation and TCF-1 was identified as a critical regulator of memory 
differentiation. Furthermore, these studies also helped identify new potential 
regulators of T cell function during an immune response. Overall, these studies 
highlight the fact that transcription factors can have overlapping functions and 
form a network to imprint a developmental program in T cells regulating their fate 
and memory differentiation. 
E. Immunity at non-lymphoid tissues 
T cells are initially activated in the spleen and lymph nodes by APCs, after 
which they migrate to non-lymphoid tissues to eliminate foreign antigens (128). In 
response to both viral and bacterial infections antigen-specific CD8+T cells have 
been shown to migrate to non-lymphoid tissues (129), and these T cells are 
uniquely geared to produce effector cytokines (129-133). Activated T cells express 
chemokine receptors, which under the influence of chemokine ligands promote T 
cell migration to sites of antigen. CXCR3 is a chemokine receptor expressed on 
activated Th1 CD4+T cells and on effector CD8+T cells (86). CXCR3 promotes 
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migration of activated CD8+T cells into non-lymphoid tissue infection sites under 
the influence of its chemokine ligands CXCL9 and CXCL10  (134, 135). Distinct 
subsets of CD8+T cells have been thought to circulate in lymphoid and non-
lymphoid tissues and can be distinguished based on their surface expression of 
CD62L and CCR7 (136). CD62LhiCCR7hi central memory T cells (Tcm), thought to 
be cytolytically inactive, lack immediate effector functions and circulate through 
lymphoid organs, whereas CD62LloCCR7lo effector memory T cells (Tem) can 
immediately respond to secondary challenge and circulates through non-
lymphoid tissues. However, recent studies have shown that both Tcm and Tem 
mediate an efficient recall response and that CD62L is not the best predictor of a 
memory T cell pool (88). Consistent with this study, I also found that CD62L and 
CCR7 were uniformly down-regulated on virus-specific CD8+T cells from both 
lymphoid and non-lymphoid tissues and could not be used as a predictor of 
memory precursors during resolution of the immune response. 
Presence of memory T cells at non-lymphoid tissues is critical for 
protection against secondary challenge. Tissue-retentive memory CD4+ and 
CD8+T cells have been shown to be important in protection against HSV and 
respiratory virus infections in mice (131, 137, 138). Resident memory CD8+T cells in 
the non-lymphoid tissues were shown to be important for induction of a rapid 
local recall response and recruitment of circulating memory CD8+T cells to the 
site of infection (133). Our lab has shown that during and after silencing of the 
immune response, LCMV-specific CD8+T cells in the non-lymphoid tissues are 
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more resistant to apoptosis than those in the lymphoid organs (139). Virus-
specific CD8+T cells in the non-lymphoid tissues expressed lower levels of Fas 
and FasL and were resistant to activation-induced cell death (AICD). This 
differential in apoptosis could account for persistence of long-lived virus-specific 
memory CD8+T cells at high frequencies in the non-lymphoid tissues, serving as 
frontline defense against secondary virus challenge.  
F. P14 and SMARTA TCR transgenic mice 
LCMV induces a strong CTL response which comprises of T cells capable 
of recognizing distinct viral epitopes. The T cell receptor (TCR) recognizes the 
viral peptides presented in the context of Class I (for CD8+T cells) or Class II (for 
CD4+T cells) MHC. The TCR comprises of disulfide linked α and β glycoproteins 
generated by somatic rearrangement of germline-encoded variable and constant 
gene segments. Due to the polymorphic nature of α and β chain rearrangement, 
different TCR on the surface of CD8+T cells can be utilized to generate an 
epitope specific response against the virus. Therefore, the presence of T cells 
with different TCR re-arrangements recognizing the same epitope along with the 
generation of a T cell response to distinct viral epitopes makes quantitating and 
analyzing the total antigen-specific T cell response difficult. 
The identification of CD8+T and CD4+T cell epitopes for LCMV in the last 
20 years has allowed us to study the generation and maintenance of virus-
specific T cell responses (140-144). Amongst the LCMV epitopes identified 
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immunodominant NP396 and GP33 and subdominant GP276 and NP205 have 
been widely used to study LCMV specific CD8+T cell responses. The utilization of 
at least two techniques: a) Class I MHC tetramers containing viral peptides to 
identify antigen-specific cells and b) intracellular cytokine secretion assays (ICS) 
to measure IFNγ secretion at a single cell level in response to viral peptides have 
shown that at the peak of the immune response to LCMV, 80-95% of CD8+T cells 
are virus-specific (145, 146)(147). 
TCR transgenic mice which express single TCR α and β chains generated 
from a single antigen-specific T cell clone have further helped study various 
aspects of the immune response. P14 TCR transgenic mice express Vα2 and 
Vβ8.1 TCR chains under the control of the H2Kb promoter and IgG enhancer (148-
150). CD8+T cells in the P14 TCR transgenic mice are specific for the 
immunodominant GP33-41 epitope. Therefore, adoptive transfer of P14 CD8+T 
cells into a congenic host allows us to track a single-TCR expressing LCMV-
specific CD8+T cell response. SMARTA TCR transgenic mice expressing a MHC 
Class II restricted TCR to study LCMV-specific CD4+T cell responses have also 
been generated (151). The CD4+T cells in these mice express Vα2 and Vβ8.1 
TCR chain specific for the LCMV GP61-80 epitope. Therefore, adoptive transfer of 
SMARTA CD4+T cells into a congenic host allows us to track a single-TCR 
expressing LCMV-specific CD4+T cell response. For studies presented in this 
thesis, we have done adoptive transfer studies with P14 CD8+T and SMARTA 
CD4+T cells to track LCMV-specific CD8+ and CD4+T cell responses. 
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G. Transcription factor ROG/Zbtb32 
ROG is a transcription factor belonging to the POZ (Pox virus and zinc 
finger) family of proteins. Members of the POZ family have a BTB (broad 
complex, tramtrack, and bric-a-brac) domain at the N terminus for protein-protein 
interaction and a Zn finger domain at the C terminus for DNA binding (152). The 
majority of the POZ family members are transcriptional repressors. In yeast two-
hybrid screens ROG was identified as a GATA-3 interacting protein (transcription 
factor regulating development, differentiation and activation of Th2 cells). ROG 
was shown to repress GATA-3 transactivation and hence the name repressor of 
GATA-3 (ROG) was coined (152). 
ROG is expressed in T and B cells upon activation and in in vitro assays 
was shown to inhibit both Th1 and Th2 cytokine production (152). In type 2 CD8+T 
cells (Tc2) ROG inhibited IL-4 gene activation by recruiting histone deacetylase 
(HDAC) 1 and 2 to induce repressive histone modifications (153). ROG-deficient T 
cells could differentiate into Th1 and Th2 cells, but had enhanced proliferation 
and cytokine production in response to in vitro anti-CD3 stimulation, suggesting 
that ROG negatively regulated T cell activation (154-156). Th1 immune responses 
of ROG-deficient and wild-type control mice were similar in an EAE (experimental 
autoimmune encephalomyelitis) induction model, suggesting that ROG-deficient 
mice had no defect in mounting a Th1 immune response (156). A recent study 
showed that in B cells, ROG interacts with the transcription factor Blimp-1 and 
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promotes plasma cell differentiation by suppressing Class II MHC expression 
(157). 
Therefore, current literature supports a model where ROG is an early 
induced gene upon T cell activation and may negatively regulate T cell activation. 
However, our understanding of the function of ROG in regulating in vivo T cell 
responses during both acute and chronic viral infections is currently lacking. 
H. Thesis objectives 
Generation of memory T cells is the hallmark of a successful immune 
response. Long-lived memory CD8+T cells populate both lymphoid organs and 
non-lymphoid tissues to provide protection to secondary challenge by the same 
pathogen. Our lab has previously shown that during and after resolution of the 
immune response to LCMV, virus-specific CD8+T cells in the non-lymphoid 
tissues (fat-pad and peritoneum cavity) are more resistant to apoptosis than 
those in the lymphoid organs (spleen, inguinal lymph nodes and mesenteric 
lymph nodes), allowing for a higher frequency of memory T cells to persist in the 
non-lymphoid tissues. However, the mechanisms regulating tissue-dependent 
differences in CD8+T cell apoptosis have not yet been elucidated. I questioned 
whether tissue-dependent apoptotic differences in LCMV-specific T cells were 
due to enrichment of non-lymphoid tissues with CD8+T cells of a phenotype 
intrinsically resistant to apoptosis, due to preferential migration of non-apoptotic 
CD8+T  cells into peripheral sites, and/or due to tissue environment factors that 
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protect against cell death. I found that multiple mechanisms account for tissue-
dependent differences in CD8+T cell apoptosis seen during resolution of the 
immune response. Non-lymphoid tissues were enriched in memory phenotype 
CD8+T cells which were intrinsically resistant to apoptosis irrespective of the 
tissue environment. Furthermore, I found that apoptosis-resistant CD8+T cells 
may preferentially migrate into the non-lymphoid tissues where the availability of 
tissue-specific factors may enhance memory cell survival. 
Transcription factors can regulate the balance between effector-memory 
CD8+T cell generation. Blimp-1 is a transcriptional factor, and drives the 
differentiation of CD8+T cells towards the short-lived effector fate, and the 
absence of Blimp-1 leads to the development of memory precursor CD8+ T cells 
that are better at producing IL-2. Although Blimp-1 is known to regulate a number 
of target genes mediating plasma cell differentiation (90), only a few targets of 
Blimp-1 in CD8+ T cells have been identified. The objective of this project was to 
identify the mechanism by which Blimp-1 regulates CD8+T cell differentiation. 
Genome-wide ChIP-sequencing analysis done by Dr. HyunMu Shin identified 
CD25 and CD27 genes as direct targets of Blimp-1.  Furthermore, we could show 
that suppression of CD25 and CD27 expression by Blimp-1 is one of the 
mechanisms by which Blimp-1 dictates the fate of effector CD8+ T cells. 
ROG is a transcription factor, and several in vitro studies have suggested 
that ROG may regulate the activation of CD4+ and CD8+ T cells. I investigated 
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the role of ROG in the development of anti-viral CD8+ T cell responses during 
acute and chronic LCMV infection. By using mice deficient in ROG I showed that 
ROG plays a unique non-redundant role in negatively regulating CD8+T cell 
responses during acute and chronic LCMV infection, and that it might be an 
important regulator of effector and memory CD8+T cell generation.  
Overall the studies highlighted in this thesis elucidate the mechanisms 
which may regulate tissue-dependent differences in CD8+T cell apoptosis during 
acute LCMV infection. These studies will also help us gain insight into 
transcriptional regulation of CD8+T cell effector-memory differentiation during 
viral infections. 
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CHAPTER II: MATERIALS AND METHODS 
A. Mice 
C57BL/6J male mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). P14 transgenic mice were bred onto CD90.1 (Thy1.1) and CD45.1 (Ly5.1) 
C57BL/6 backgrounds to distinguish the transgenic cells from wild-type (WT) 
cells in the C57BL/6 (CD90.2+ (Thy1.2) CD45.2+ (Ly5.2)) mice. Tcf7-/- mice on the 
C57BL/6 background have been described previously (158), and were bred at the 
UMMS. Tcf7+/+ littermate mice were used as WT controls. The LCMV GP61-
specific CD4 transgenic SMARTA CD45.1+ mice (151) were bred at UMMS. CD4-
Cre mice were a gift from Joonsoo Kang at UMMS. Prdm1fl/fl mice have been 
described previously (159). This line was crossed to CD4-cre+ transgenic mice, 
thereby deleting Blimp-1 in all αβ T cells (referred to as Prdm1-/-). In Chapter IV, 
unless otherwise indicated, C57BL/6 CD4-Cre+ transgenic mice were used as 
WT controls. For some experiments, P14+ Prdm1ﬂ/ﬂ mice were crossed to 
Granzyme B-Cre+ transgenic mice for the deletion of Blimp-1 in activated CD8+T 
cells, as previously described (94). Zbtb32-/- mice have been described previously 
(156), and were crossed to P14 TCR transgenic CD90.1 or CD45.1 mice to study 
the role of ROG in intrinsic CD8+T cell function. Mice were bred and housed in 
specific pathogen free conditions at the UMMS in accordance with the guidelines 
of the Institutional Animal Care and Use Committee of UMMS (IACUC). 
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B. Preparation of leukocytes 
Mice were sacrificed by cervical dislocation. PECs were collected by lavaging 
with 10 ml cold RPMI 1640 medium (Gibco). Spleen, lymph nodes and fat-pads 
were ground between glass microscope slides to prepare single cell 
suspensions. To remove contaminating erythrocytes, leukocyte preparations 
were treated with 0.84% ammonium chloride (NH4Cl). 
C. Virus 
LCMV, strain Armstrong, was propagated in BHK cells as previously described 
(160). Mice were inoculated intraperitoneally (i.p) with 0.1 ml containing 5 x 104 
PFU (plaque forming units) of the Armstrong strain of LCMV in PBS. The Clone 
13 variant of LCMV was propagated in baby hamster kidney BHK21 cells (12) and 
titrated by plaque assay on Vero cells. Mice were infected intravenously (i.v) with 
2 × 106 (high dose) PFU of LCMV, strain Clone 13. In some experiments, mice 
were inoculated i.p with 1 × 106 PFU of Vaccinia virus (VACV), strain Western 
Reserve. 
D. Antibodies, flocytometry and intracellular cytokine staining 
Leukocytes were stained for CD8α (53-6.7; BD Pharmigen), CD8β (YTS156.7.7; 
Biolegend), CD4 (RM4-5; BD Pharmigen), CD44 (IM7; eBiosciences), Thy1.1/ 
CD90.1 (HIS51; eBiosciences), Ly5.1/CD45.1 (A20; Biolegend), KLRG-1 (2F1; 
eBiosciences), CD127 (A7R34; eBiosciences), CD27 (LG.310; BD Pharmingen), 
CXCR3 (CXCR3-173; Biolegend), CXCL9 (MIG-2F5.5; eBiosciences), TCF-1 
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(C63D9; Cell Signaling), EOMES (Dan11mag; eBiosciences), Bcl-2 (3F11; BD 
Pharmingen), CD122 (TM.BETA-1; BD Pharmigen), CD70 (FR70; Biolegend), 
CD25 (PC61; BD Pharmigen), Granzyme B (NGZB; eBiosciences), CD62L 
(MEL-14; BD Pharmigen), CD155 (TX56; Biolegend). For TCF-1 intracellular 
staining AF647 conjugated goat-anti rabbit (Invitrogen) secondary antibody was 
used. To stain for intracellular antigens FOXP3/Transcription factor staining 
buffer kit (eBiosciences) was used. For intracellular cytokine secretion assays 
leukocytes were incubated for 5 hours ex-vivo with 1µM LCMV-specific NP396-404, 
GP33-41 or GP61–80 peptide or 1µM VACV-specific B8R or K3L peptide in the 
presence of Golgi Plug (BD Biosciences). Cells were then permeabilized using 
the cytofix/cytoperm kit (BD Biosciences) followed by intracellular staining for 
IFNγ (XMG1.2; eBiosciences), IL-2 (JES65H4; BD Pharmigen) and TNF (MP6-
XT22; Biolegend). Samples were analyzed on an LSRII flow cytometer (Becton 
Dickinson), and data were further analyzed using FlowJo (Tree Star).  
E. H2Db MHC tetramer staining 
For identification of virus-specific CD8+T cells by Class I MHC tetramer staining 
2x106 leukocytes were incubated with PE- or APC-conjugated  H-2Db-restricted 
NP396–404 or GP33-41 tetramers for 1 hr at 4C. 
F. Annexin V, TUNEL and Caspase-3 assay 
Leukocytes were stained for Annexin V (eBiosciences) and samples were 
analyzed live according to the manufacturers’ protocol. 7AAD (BD Pharmingen) 
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was used to gate out dead and late-apoptotic populations. For TUNEL and 
Caspase-3 staining, leukocytes were incubated at 37C directly ex-vivo for 5 
hours in culture media. TUNEL assay (APO-DIRECT KIT; BD Pharmigen) and 
active Caspase-3 (C92-605; BD Pharmigen) staining was carried out according 
to the manufacturers’ protocol. For active Caspase-3 and TCF-1 co-staining, 
after rabbit TCF-1 primary and goat anti-rabbit secondary antibody staining 
samples were incubated with unlabeled rabbit IgG (Southern Biotech) to saturate 
the goat anti-rabbit secondary antibody. Cells were then incubated with rabbit 
active Caspase-3 antibody. For inhibiting Caspase dependent apoptosis 
leukocytes were cultured for 5 hours ex-vivo in the presence of 100µM Z-VAD-
FMK (Enzo Life Sciences). 
G. pSTAT5 staining 
Freshly isolated leukocytes were plated in 96 well plates and stimulated with IL-7 
cytokine (Pepro Tech) as shown in Figure III-30. Cells were fixed on ice with BD 
cytofix (BD Biosciences) for 15 min and stained with surface antibodies after 
which cells were permeabilized with BD Phosflow perm buffer III (BD 
Biosciences) for 30 mins on ice. Cells were then stained intracellularly for 
pSTAT5 (pY964; BD Biosciences). 
H. Adoptive transfer studies, T cell isolation and cell labeling 
Unless otherwise noted virus-specific CD8+T cell responses were tracked by 
transferring 2 x105 P14 splenocytes (CD90.1 or CD45.1) into a congenic 
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C57BL/6 host (CD90.2+ CD45.2+). Splenocytes from day 7 LCMV-infected mice 
were labeled with CFSE (2µM) or DDAO (0.5µM), washed with HBSS and 
adoptively transferred into an infection matched C57BL/6 host as shown in 
Figure III-28. The schematic for adoptive transfer of CD25hi/lo and CD27hi/lo 
CD8+T cells is shown in Figure IV-13 and IV-20, respectively. Recall responses 
of Zbtb32-/- or WT P14 CD8+T cells at day 30 post-LCMV infection were 
compared as shown in the schematic in Figure V-18. Wherever noted, total 
CD8+T cells were isolated with the CD8+T Cell Isolation Kit II (Miltenyi Biotec), 
and LCMV-specific P14+CD8+T cells were further sorted on a FACS Aria cell 
sorter.  
I. BrdU staining 
WT and Prdm1-/- mice were infected with LCMV, and then injected via i.p with 
100ul of 10mg/ml BrdU (Bromodeoxyuridine) solution (BD Pharmingen) at day 7 
or 8 post-infection. Twelve hours later, splenocytes were harvested and GP33-41 
tetramer-positive CD8+T cells were analyzed for BrdU incorporation according to 
the manufacturers’ instructions. 
J. Apyrase and FTY720 treatment 
Day 7 LCMV infected mice were i.p injected with 5U Apyrase (New England 
Biolabs) or succinate buffer control and were sacrificed after 6 hours. FTY720 
(Cayman Chemical Company) at 1 mg/kg was given i.v (day 5 and 6) and i.p 
(day7) post-LCMV infection as shown in Figure III-21. 
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K. In vitro T cell stimulation and proliferation assay. 
CD8+T cells were isolated from WT or Prdm1-/- mice at day 7 after LCMV 
infection. CD8+T cells were labeled with CFSE (2uM), washed, and were cultured 
for 2 days with or without the indicated cytokines. IL-1β, IL-6, IL-12, IL-18, IL-21, 
and IL-23 were purchased from R&D. IL-2 and IL-4 were purchased from BD 
Biosciences. IFNγ, IL-7, and IL-15 were purchased from PeproTech. IFNβ was 
purchased from PBL InterferonSource. Cytokine concentrations were as follows: 
IFNβ (200 U), IFNγ (200 U), IL-1β (50 ng/ml), IL-2(40 ng/ml), IL-4 (40 ng/ml), IL-6 
(40 ng/ml), IL-7 (20 ng/ml), IL-12 (20 ng/ml),IL-15 (20 ng/ml), IL-18 (20 ng/ml), IL-
21 (20 ng/ml), and IL-23 (40 ng/ml). 
L. Plaque assay for LCMV 
Spleens from LCMV Armstrong infected WT or Prdm1-/- or Zbtb32-/- mice were 
ground and titrated by plaque assay on Vero cells, as previously described (160). 
The same protocol was used to analyze viral titers from spleen and liver of day 
10 LCMV Clone 13 infected WT or Zbtb32-/- mice. 
M. Histology 
Lung and liver tissues from high dose LCMV Clone 13 infected mice were fixed in 
10% paraformaldehyde and stained with hematoxylin and eosin (H&E). 
N. RT-PCR 
Total RNA was isolated using an RNeasy mini kit (Qiagen), converted to cDNA 
(Quantitect Reverse Transcription kit, Qiagen), and analyzed by real-time 
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quantitative PCR amplification on a Bio-Rad iCycler by using Quanti-Fast RT-
PCR SYBR green kit (Qiagen), according to the manufacturers’ protocol. Primers 
for Cxcl9 and Cxcl10 were purchased from Qiagen. Zbtb32 and Actb primers 
were purchased from Real Time Primers, LLC. 
O. Microarray analysis 
Day 6 LCMV infected P14 TCR transgenic WT or Zbtb32-/- CD8+T cells were 
sorted on FACS Aria cell sorter and total RNA was isolated using an RNeasy 
mini kit (Qiagen). Affymetrix GeneChip Mouse Gene 1.0 ST Array (Affymetrix) 
was used, and data were analysed on Affymetrix Transcriptome Analysis 
Console (TAC) software. 
P. Statistical analysis 
In chapter III data significance (p values) was calculated using an unpaired 
Students t test. All error bars in chapter III of the manuscript represent Standard 
Deviation from the mean (StDev). In Chapters IV and V the statistical difference 
between samples was analyzed with an unpaired Students t test. All error bars in 
Chapter IV and V represent the Standard Error of the Mean (SEM). 
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CHAPTER III: MECHANISMS REGULATING TISSUE-DEPENDENT 
DIFFERENCES IN CD8+T CELL APOPTOSIS DURING ACUTE LCMV 
INFECTION 
The majority of intracellular pathogen infections are initiated at non-
lymphoid tissue sites. T cells get primed and activated in the lymphoid organs 
after which they migrate to non-lymphoid tissues and produce effector cytokines 
to eliminate the pathogen (128, 129, 131, 132). The presence of memory T cells in 
non-lymphoid tissues has been shown to be critical for protective immunity in 
various viral infection models (133, 137, 138, 161). Our lab has previously shown 
that virus-specific CD8+T cells in the non-lymphoid tissues were more resistant to 
apoptosis as compared to the lymphoid organs during the resolution and memory 
phase of the immune response to an acute LCMV infection (139). That study 
provided a mechanism by which memory T cells would be protected and retained 
at a higher frequency in the non-lymphoid tissues to provide protection to 
secondary challenges. However, the mechanisms which regulate tissue-
dependent differences in CD8+T cell apoptosis have not been investigated so far. 
I hypothesized that the increased resistance to apoptosis seen in virus-
specific CD8+T cells in the non-lymphoid tissues could be due to any of several 
factors: 1) enrichment of non-lymphoid tissues with a phenotype of cells which 
are intrinsically resistant to apoptosis, 2) preferential migration of apoptosis-
resistant CD8+T cells to non-lymphoid tissues during an immune response, 3) the 
presence of tissue-specific survival factors which promoted stability of CD8+T 
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cells in the non-lymphoid tissues, 4) efficient removal of pre-apoptotic T cells 
from non-lymphoid tissue sites contributing to the phenotype. In this chapter I 
provide evidence that increased resistance to apoptosis seen in virus-specific 
CD8+T cells in the non-lymphoid tissues was due to a combination of several 
factors. Non-lymphoid tissues were enriched in memory-phenotype CD8+T cells, 
which were intrinsically resistant to apoptosis irrespective of the tissue 
environment. Furthermore, I show that apoptosis-resistant CD8+T cells 
preferentially migrate into the non-lymphoid tissues where the availability of 
tissue-specific factors may enhance memory cell survival. 
A. CD8+T cells in the non-lymphoid tissues are resistant to apoptosis 
Our lab has previously documented that LCMV-specific CD8+T cells in the 
non-lymphoid tissues reacted less with the pre-apoptotic marker Annexin V (139) 
and that adoptively transferred Annexin V-reactive cells failed to develop into 
memory cells (65). To track virus-specific CD8+T cell responses, splenocytes of 
P14 transgenic mice (harboring CD8+T cells specific for the LCMV GP33-41 
epitope) were adoptively transferred into a congenic C57BL/6 host followed by 
infection with LCMV, strain Armstrong. At day 9 post-LCMV infection, lymphoid 
(spleen, inguinal lymph nodes, mesenteric lymph nodes) and non-lymphoid (fat-
pad, PEC) tissues were harvested. Wherever possible I have tried to compare 
the phenotype in multiple organs, but for most of the studies PEC were used as a 
representative of non-lymphoid tissue and spleen was used as a representative 
of lymphoid organs. As shown in Figure III-1 and consistent with the previous 
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results, I found that LCMV-specific CD8+T cells in the non-lymphoid tissues 
reacted less with the pre-apoptotic marker Annexin V. The plots in Figure III-1 
were gated on 7AAD negative “viable” lymphocytes to distinguish pre-apoptotic 
cells from late-apoptotic populations. The differences in Annexin V reactivity of 
virus-specific CD8+T cells from lymphoid and non-lymphoid tissues are further 
highlighted by differences in mean fluorescent intensity (MFI) of Annexin V within 
the antigen-specific T cell population (Figure III-1). However, because Annexin V 
can also bind at some level to activated and proliferating T cells (63, 64), I 
reassessed bona-fide end stage apoptotic cells using the TUNEL assay to detect 
fragmented DNA, which is a classic hallmark of apoptosis. Detection of end stage 
apoptotic cells directly ex-vivo is difficult, as most of them are efficiently cleared 
in vivo by phagocytes (162). I therefore cultured cells directly ex-vivo for 5 hours 
to detect TUNEL positive end stage apoptotic cells. Cells from five mice were 
pooled for each experiment to perform multiple assays simultaneously.  In 
accordance with our previous observations, I found that at day 9 post-LCMV 
infection, virus-specific CD8+T cells in the non-lymphoid tissues including the 
peritoneal cavity and fat-pad were more resistant to apoptosis and less reactive 
with TUNEL than those in the lymphoid organs, including spleen, inguinal lymph 
nodes and mesenteric lymph nodes (Figure III-2).  In the previous studies tissue- 
dependent apoptotic differences persisted at least up to 4 months post-LCMV 
infection, and the phenotype was shown to be long lasting (139). In accordance 
with the previous observations, I found that at day 35 post-LCMV infection 
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(memory phase), virus-specific CD8+T cells in the peritoneal cavity (non-
lymphoid tissue) remained less apoptotic than those in the spleen (lymphoid 
organ) as detected by Annexin V assay (Figure III-3). 
Caspases belong to a family of cysteine proteases which play an essential 
role in apoptosis.  Apoptotic T cells have been shown to have increased levels of 
activated Caspase-3 (60), and T cells from Caspase-3-deficient mice have 
reduced susceptibility to AICD driven by CD3 crosslinking and Fas ligands (61). 
Therefore, I tested whether increased apoptosis of virus-specific CD8+T cells in 
lymphoid organs correlated with increased Caspase-3 activation. Virus-specific 
CD8+T cells from day 9 LCMV-infected PEC or spleen were cultured for 5 hours 
directly ex-vivo and stained for active-Caspase 3. Consistent with the increased 
apoptosis, virus-specific CD8+T cells in spleen also had higher levels of active 
Caspase-3, in comparison to the PEC (Figure III-4). To further confirm that the 
CD8+T cell apoptosis was caspase dependent, day 9 splenocytes from LCMV-
infected mice were incubated for 5 hours in the presence of the pan-caspase 
inhibitor ZVAD-FMK, which irreversibly inhibits activity of caspase family 
proteases and blocks apoptosis. The virus-specific CD8+T cells from the spleen 
were less TUNEL reactive when incubated in the presence of ZVAD-FMK (Figure 
III-5) as compared to control-treated cells, suggesting that ZVAD-FMK was 
blocking apoptosis and that the CD8+T cell apoptosis required caspases.  
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Cellular apoptosis results from the interplay between pro and anti-
apoptotic factors, and higher levels of the anti-apoptotic Bcl-2 in effector CD8+T 
cells have been shown to be important in counteracting the effects of pro-
apoptotic Bim, thereby allowing for survival of cells during contraction of the 
immune response (54). Activated virus-specific CD8+T cells that become memory 
cells also express higher levels of Bcl-2 (53). I therefore compared Bcl-2 
expression in virus-specific CD8+T cells from PEC and the spleen. Virus-specific 
CD8+T cells in the PEC expressed modestly higher levels of Bcl-2 as compared 
to those from the spleen at day 9 post-LCMV infection as shown by the overlay in 
Figure III-6. The MFI of Bcl-2 expression in antigen-specific CD8+T cells from 
PEC was also higher than in the spleen as shown by the histogram in Figure III-
6. Therefore by several criteria I could show that virus-specific CD8+T cells in the 
peripheral non-lymphoid tissues are more resistant to apoptosis than those in the 
lymphoid organs.  
B. Non-lymphoid tissues are enriched for apoptosis-resistant memory 
phenotype CD8+T cells 
          I next sought to determine why CD8+T cells in the peripheral tissues were 
more resistant to apoptosis. I hypothesized that non-lymphoid tissues might be 
enriched in an antigenic phenotype of cells which were intrinsically resistant to 
apoptosis. CD8+T cells expressing high amounts of  IL-7R have been shown to 
express more Bcl-2 and to be relatively resistant to apoptosis (65, 72). Surface 
expression of IL-7Rα along with KLRG-1 (inhibitory receptor found on T and NK 
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cells) has been used to identify cells which will preferentially make it into memory 
(Memory Precursor effector cells: IL-7Rhi KLRG-1lo) or die during contraction of 
the immune response (Short-Lived effector cells: IL-7Rlo KLRG-1hi) (69, 74). At 
day 8 post-LCMV infection virus-specific CD8+T cells from lymphoid organs 
(spleen, ILN, MLN) and non-lymphoid tissues (PEC, fat-pad) were stained 
directly ex-vivo for IL-7Rα and KLRG-1. I found that a higher proportion of virus-
specific CD8+T cells with a MPEC phenotype (IL-7Rhi KLRG-1lo) were present in 
the non-lymphoid tissues as compared to lymphoid organs at day 8 post-LCMV 
infection (Figure III-7). Tissue-dependent apoptotic differences persist long term 
after the resolution of the immune response and I questioned whether PEC were 
enriched in memory phenotype cells when compared to spleen during memory 
phase of the immune response. I found a higher frequency of memory phenotype 
virus-specific CD8+T cells persisted in the PEC at day 40 post-LCMV infection 
compared to the spleen (Figure III-8).  
Apart from IL-7Rα and KLRG-1, other phenotypic markers have been 
used to identify cells with a memory phenotype. CD27 is a co-stimulatory 
receptor of the TNF-R family, and stimulation of CD27 on CD8+T cells in vitro has 
been shown to promote survival (84, 163). In vivo blockade of CD27 during 
resolution of the immune response promotes apoptosis of virus-specific CD8+T 
cells (83).  Therefore, I compared CD27 expression on virus-specific CD8+T cells 
from PEC and spleen at day 8 post-LCMV infection. A higher proportion of virus-
specific CD8+T cells in the PEC expressed CD27 as compared to those in the 
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spleen, as shown in Figure III-9. Although CD27 is known to be expressed in 
memory phenotype CD8+T cells, correlation of high CD27 expression with 
decreased apoptosis during resolution of the immune response has not been 
tested. To confirm that CD27 expression on CD8+T cells correlates with survival, 
I compared apoptotic profiles of CD27hi and CD27lo CD8+ T cells. Virus-specific 
CD8+T cells from PEC or the spleen were cultured for 5 hours directly ex-vivo at 
day 8 post-LCMV infection and stained for CD27, TUNEL and active Caspase-3. 
As hypothesized, I found that cells expressing higher levels of CD27 from both 
the PEC and spleen reacted less with apoptotic markers TUNEL and active 
Caspase-3 at day 8 post-LCMV infection (Figure III-9). Therefore, CD27-
expressing virus-specific CD8+ T cells were less apoptotic, and were present at a 
higher proportion in the PEC. CXCR3 is another marker preferentially expressed 
on memory phenotype CD8+T cells (69). Therefore, I compared CXCR3 
expression on virus-specific CD8+T cells from PEC and spleen at day 8 post- 
LCMV infection. A higher proportion of virus-specific CD8+T cells in the PEC 
expressed CXCR3 as compared to those in the spleen, as shown in Figure III-10. 
Although CXCR3 is known to be expressed in memory phenotype CD8+T cells, 
correlation of high CXCR3 expression with decreased apoptosis during resolution 
of the immune response has not been tested. To confirm that CXCR3 expression 
on CD8+T cells correlates with survival, I compared apoptotic profiles of CXCR3hi 
and CXCR3lo CD8+ T cells. As hypothesized, I found that cells expressing higher 
levels of CXCR3 from both the PEC and spleen reacted less with apoptotic 
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markers TUNEL and active Caspase-3 at day 8 post-LCMV infection (Figure III-
10). Thus, CXCR3-expressing virus-specific CD8+ T cells were less apoptotic, 
and were present at a higher proportion in the PEC. Therefore, by several 
criteria, I could show memory T cells resistant to apoptosis were present at a 
higher frequency in PEC as compared to the spleen. Moreover, during resolution 
of the immune response CD27 and CXCR3 expression on CD8+T cells correlated 
with decreased apoptosis. Interestingly, CD27- and CXCR3-expressing CD8+T 
cells reacted less with apoptotic markers TUNEL and active Caspase-3 
irrespective of the tissue environment, suggesting that CD27- and CXCR3-
expressing cells were intrinsically resistant to apoptosis. 
The ability of virus-specific CD8+T cells to produce multiple cytokines, 
such as IFNγ, TNF and IL-2, simultaneously during viral infection is a primary 
indicator of their functional capacity, and  IL-2-producing CD8+T cells are more 
likely to become memory cells than those that do not make IL-2 (79). I examined 
the cytokine repertoire of virus-specific CD8+T cells isolated from PEC and 
spleen. Day 8 LCMV-infected splenocytes or PEC were cultured directly ex-vivo 
for 5 hours in the presence of LCMV-specific GP33 or NP396 peptide epitopes. 
As shown in Figure III-11, virus-specific CD8+T cells from PEC were enriched in 
IFNγ, TNF and IL-2 triple producers as compared to the spleen (% indicated on 
top right represent triple cytokine producers), indicating that T cells in the PEC 
were functionally superior than in the spleen during resolution of the immune 
response. I have shown that during resolution of the immune response CD27 and 
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CXCR3 expression on CD8+ T cells correlated with decreased apoptosis. 
However, as a further correlate of CD27 and CXCR3 expression with functional 
memory CD8+T cell pool I compared IL-2 production in CD27- and CXCR3-
expressing virus-specific CD8+T cells. As shown in Figure III-12 CD27hi and 
CXCR3hi virus-specific CD8+T cells were enriched in IFNγ, TNF and IL-2 triple 
cytokine producers compared to CD27lo and CXCR3lo populations both in the 
spleen and PEC, suggesting that expression of these markers represented 
CD8+T cells that could become functional memory cells. Interestingly, a higher 
frequency of CD27hi and CXCR3hi CD8+T cells in the PEC produced multiple 
cytokines when compared to the CD27hi and CXCR3hi CD8+T cells in the  spleen 
respectively (Figure III-12), suggesting that PEC tissue environment was 
promoting generation of functional memory CD8+T cells.  Overall, these results 
indicated that the non-lymphoid tissues are enriched in memory T cells that are 
more functional and resistant to apoptosis. 
C. Virus-specific CD8+T cells in the non-lymphoid tissues express 
transcription factors correlating with a memory phenotype 
Few transcription factors that can regulate CD8+T cell differentiation into effector 
and memory cells during an immune response have been identified. Therefore, in 
addition to examining cell surface antigens as correlates of resistance to 
apoptosis, I sought for transcription factors that might regulate the processes. 
TCF-1 is a transcription factor which promotes generation and maintenance of 
functional memory CD8+T cells (104-106). Since the non-lymphoid 
 
 55 
 
 56 
tissue environment was enriched in memory phenotype CD8+T cells, I 
determined TCF-1 expression in the T cells from PEC as a representative of non-
lymphoid tissue and spleen as a representative of lymphoid organ. Virus-specific 
P14+CD8+T cells or activated CD44hi CD8+T cells were intracellularly stained for 
TCF-1 at day 9 post-LCMV infection. I found that a higher proportion of virus-
specific and activated CD44hi CD8+T cells expressed TCF-1 in the PEC as 
compared to the spleen (Figure III-13). The expression level of TCF-1 was also 
higher in virus-specific and activated CD44hi CD8+T cells in the PEC when 
compared to spleen as shown by the MFI (Figure III-13). Consistent with the 
increased survival of CD8+T cells in non-lymphoid tissues during memory phase 
of the immune response, I found that a higher proportion of virus-specific CD8+T 
cells in the PEC expressed TCF-1 at day 30 post-LCMV infection when 
compared to the spleen (Figure III-14). Although TCF-1 deficiency has been 
shown to limit the generation of CD44hi CD62Lhi (central memory) CD8+T cells 
(105), a correlation of high TCF-1 expression with memory phenotype CD8+T cells 
and decreased apoptosis during resolution of the immune response has not been 
tested. At day 9 post-LCMV infection splenocytes and PEC were cultured directly 
ex-vivo for 5 hours and expression of memory phenotype markers and active  
Caspase-3 was compared in TCF-1hi and lo P14 CD8+T cells. I found that in both 
the tissues tested (PEC and spleen) virus-specific CD8+T cells expressing high 
amounts of TCF-1 were enriched in MPECs (IL-7Rhi KLRG-1lo), with most 
expressing CD27 and CXCR3. TCF-1hi cells were also less apoptotic, as 
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revealed by active Caspase-3 staining (Figure III-15 A and B). These results 
demonstrate that the PEC environment was enriched in TCF-1hi CD8+T cells, and 
that this correlated with increased memory and increased survival. LEF-1 is a 
transcription factor acting downstream in the Wnt signaling pathway (101), and 
TCF-1 and LEF-1 have redundant roles in promoting thymocyte  maturation (102). 
Loss of TCF-1 and LEF-1 in CD8+T cells was shown to completely abrogate 
development of memory precursor effector cells (164). Since LEF-1 and TCF-1 
are known to co-operate in generation of memory CD8+T cells, I wanted to 
compare LEF-1 expression in virus-specific CD8+T cells in the PEC and spleen. I 
found that at day 10 post-LCMV infection, PECs had a higher proportion of LEF-1 
expressing virus-specific CD8+T cells as compared to the spleen (Overlay in 
Figure III-16). The expression level of LEF-1 was also higher in virus-specific 
CD8+T cells in the PEC when compared to spleen, as shown by the MFI in 
Figure III-16.  TCF-1 has been shown to be necessary and sufficient for 
expression of EOMES, a transcription factor associated with memory CD8+T 
cells (105). EOMES has been shown to be important for induction of  CD122 (IL-
2Rβ) expression and IL-15 responsiveness in CD8+T cells (108), thereby 
promoting survival of memory T cells. I compared EOMES expression in virus- 
specific CD8+T cells in the PEC and spleen. Consistent with a higher TCF-1 
expression, a higher proportion of virus-specific CD8+ T cells in the PEC 
expressed EOMES as compared to the spleen at day 9 post-LCMV infection 
(Figure III-17). The expression level of EOMES was also higher in virus-specific 
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CD8+T cells in the PEC when compared to spleen as shown by the MFI in Figure 
III-17. Therefore, non-lymphoid tissues are enriched in virus-specific CD8+T cells 
expressing transcription factors associated with memory generation which may 
contribute to survival of CD8+T cells in the non-lymphoid tissue environment. 
D. Transcription factor TCF-1 promotes survival of CD8+T cells in the non-    
lymphoid tissues during resolution of the immune response 
Since a higher proportion of virus-specific CD8+T cells in the PEC expressed 
TCF-1, I next sought to identify whether TCF-1 was promoting survival of CD8+T 
cells in the non-lymphoid tissues. To address this question I infected TCF-1-
deficient or littermate control mice with LCMV and compared the phenotype and 
apoptotic profiles of activated CD44hi CD8+T cells at day 9 post infection. During 
an immune response to LCMV approximately 70% of the activated CD44hi CD8+T 
cells are virus-specific (145), and since we did not have P14 TCR transgenic TCF-
1-deficient mice to track LCMV-specific responses I decided to focus on CD44hi 
CD8+T cell responses.  In accordance with previous reports (104, 105), I found that 
TCF-1-deficient mice at day 9 post-infection had a decreased proportion and 
absolute number of activated CD44hi CD8+T cells in both PEC and spleen (Figure 
III-18). I then compared expression of IL-7Rα and KLRG-1 on CD44hi CD8+T 
cells in PEC and spleen of WT and TCF-1-deficient mice. As shown in Figure III-
19, the proportion of MPEC in the CD44hi CD8+T cell pool was reduced more 
dramatically in the PEC than in the spleen of the TCF-1-deficient mice at day 9 
post infection. To test whether maintenance of TCF-1 
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expression promotes survival of CD8+T cells in the non-lymphoid tissues, I 
isolated WT or TCF-1-deficient cells from spleen and PEC of day 9 LCMV-
infected mice and cultured them ex-vivo for 5 hours, followed by TUNEL staining. 
As shown in Figure III-20 activated CD44hi CD8+T cells from PEC of TCF-1-
deficient mice were more apoptotic when compared to WT littermates, with about 
twice the number of TUNEL+ cells. Supporting a previous observation (105),  we 
found no statistically significant difference in apoptosis of CD44hi CD8+ T cells 
from spleen between the TCF-1 KO and WT mice (Figure III-20). As compared to 
wild type littermate controls TCF-1-deficient mice had defects in generating a 
normal immune response, and overall numbers and proportions of CD44hi CD8+T 
cells in TCF-1-deficient mice were reduced in all the organs tested. However, 
these experiments were intrinsically controlled, and I compared activated CD44hi 
CD8+T cells from PEC and spleen of TCF-1-deficient mice. These results 
indicate that TCF-1 was more critical for the memory generation and survival of 
CD8+T cells in the PEC during resolution of the immune response. Importantly, I 
saw that CD44hi CD8+T cells in the PEC of TCF-1 KO mice were still less 
apoptotic than those in the spleen, which suggested  that additional mechanisms 
might regulate tissue-dependent differences in CD8+T cell apoptosis. 
E. Accumulation of non-apoptotic CXCR3+ CD8+ T cells in the inguinal 
lymph nodes on FTY720 treatment 
I next questioned whether tissue-dependent differences in CD8+T cell apoptosis 
were associated with preferential migration of non-apoptotic CD8+T 
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cells to the non-lymphoid tissues. To address this question I used FTY720,  an 
immunosuppressive drug which can modulate trafficking of lymphocytes and 
prevent emigration of T cells from the lymph nodes into the periphery (165-167). 
Transgenic P14+CD8+T cells were adoptively transferred into a congenic host, 
which was then infected with LCMV. Mice were treated with FTY720 at 1 mg/kg 
on days 5, 6 and 7 post-LCMV infection according to the treatment regimen 
shown in Figure III-21. FTY720 treatment was more efficacious in sequestering 
the T cells in the lymph nodes than in the spleen; therefore, I decided to focus on 
lymph nodes for further analysis. There was an increase in absolute number and 
proportion of virus-specific CD8+T cells in the inguinal lymph nodes of treated 
mice (Figure III-22), and a decrease in absolute number and proportion of virus-
specific CD8+T cells in the PEC (Figure III-22). Thus, FTY720 treatment was 
effective in preventing migration of T cells out of the lymph nodes. I reasoned 
that if non-apoptotic CD8+T cells preferentially leave the lymph nodes, blocking 
their egress should lead to accumulation of non-apoptotic CD8+T cells in those 
lymph nodes. Lymphocytes were isolated from PEC, ILN and MLN of D8 LCMV 
infected control- or FTY720-treated mice and cultured ex-vivo for 5 hours 
followed by TUNEL staining. As shown in Figure III-23, a lower percent of virus-
specific CD8+T cells in the inguinal and mesenteric lymph nodes were apoptotic 
in the FTY720-treated group as compared to the control group. There was only a 
modest increase in apoptosis of virus-specific CD8+T cells in the PEC in the 
FTY720-treated mice than the control mice (Figure III-23). Thus, these data are 
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consistent with the hypothesis that non-apoptotic CD8+T cells preferentially 
migrate into non-lymphoid tissues, and when migration is stopped, these 
apoptosis-resistant T cells accumulate in the lymph nodes. 
T cells get activated in the lymph nodes and migrate to non-lymphoid 
tissues to eliminate the antigen, a process mediated by chemokines and their 
receptors. I questioned whether certain chemokine receptors might be promoting 
preferential migration of non-apoptotic CD8+T cells to non-lymphoid tissue 
environment. CXCR3 is a chemokine receptor  shown to be important for 
migration of antigen-specific CD8+T cells to tissue effector sites (86)(134), and it 
has been previously reported that the peritoneal cavity is dominated by CXCR3+ 
Th1 CD4+ T cells (168). I have shown that a higher proportion of virus-specific 
CD8+T cells expressed CXCR3 in the PEC and that these were less apoptotic 
(Figure III-10). If CXCR3 was important for migration of non-apoptotic CD8+T 
cells out of the lymph nodes I should see an accumulation of CXCR3-expressing 
cells on FTY720 treatment. Figure III-24 shows that there was an increased 
proportion of CXCR3+ CD8+T cells accumulating in the inguinal lymph nodes on 
FTY720 treatment, suggesting that CXCR3+ CD8+T cells were normally 
preferentially migrating out of the lymph nodes into the non-lymphoid tissues. 
The next aim was to identify whether the PEC environment was expressing 
CXCR3 ligands which would attract non-apoptotic CD8+T cells. CXCR3+T cells 
migrate under the influence of the IFNγ-inducible chemokine ligands CXCL9 and 
CXCL10 (86, 87). I found that at day 8 post-LCMV infection there was a higher 
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proportion of total lymphocytes expressing CXCL9 in the PEC environment 
compared to the spleen (Figure III-25). Due to unavailability of a working 
CXCL10 antibody for FACS analysis I decided to compare the RNA message for 
CXCL9 and CXCL10 between spleen and PEC leukocytes. At day 7 post-LCMV 
infection, RNA was isolated from total PEC and spleen leukocytes and subjected 
to Q-PCR analysis with Cxcl9 and Cxcl10 primers. Figure III-26 shows that 
mRNA for CXCL9 and CXCL10 was higher 4.7 and 2.6 fold respectively, in the 
total PEC leukocytes when compared to total splenocytes at D7 post-LCMV 
infection. Thus, the PEC environment had a higher expression of CXCR3 ligands 
that could promote preferential migration of CXCR3+CD8+T cells. Overall, these 
results are consistent with the hypothesis that non-apoptotic CXCR3+ CD8+T 
cells preferentially migrate out of secondary lymphoid organs into the non-
lymphoid tissues under the influence of chemokines CXCL9 and CXCL10. This 
phenomenon may provide an additional mechanism by which healthy non-
apoptotic memory CD8+T cells populate non-lymphoid tissues to provide 
protection to secondary challenge. 
F. In Vivo PEC environment promotes survival of CD8+T cells 
So far, I have shown that virus-specific CD8+T cells in the non-lymphoid 
tissues are intrinsically more resistant to apoptosis, and that this could in part be 
due to preferential migration of non-apoptotic memory phenotype CD8+T cells 
from lymph nodes into the non-lymphoid tissues. I next addressed whether the 
PEC environment is particularly enriched with factors that can promote survival 
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and maintenance of memory CD8+T cells. To test whether the in vivo PEC 
environment promoted survival of CD8+T cells, LCMV-specific P14+ CD8+T cells 
were adoptively transferred into a congenic host followed by LCMV infection. At 
day 7 post infection, I isolated splenocytes which were labeled with tracking dyes 
CFSE or DDAO and transferred back into an infection-matched host via the i.v or 
i.p route respectively, as shown in Figure III-27. Splenocytes and PEC were 
isolated from the infection-matched host mice 36 hours post transfer. I used 
tracking dyes to distinguish between cells which were transferred into the same 
host via the i.v or i.p route. Thus, day 7 infected splenocytes (which are highly 
apoptotic) were labeled and introduced into the spleen or the PEC environment 
of the same infection-matched host  to address whether the tissue environment 
contributed to CD8+T cell survival. As shown in Figure III-28, donor P14+CD8+T 
splenocytes which were introduced directly into the PEC environment via the i.p 
route were less apoptotic as compared to the P14 CD8+T cells which were 
present in the spleen and introduced via the i.v route. A small number of donor 
P14+CD8+T splenocytes given intravenously were found in the PEC and were 
also less apoptotic when compared to the donor CD8+T cells which populated the 
spleen (data not shown). As shown in Figure III-28, I found that transferred P14 
CD8+T cells which were present in the PEC environment had higher expression 
of the memory marker CD27 when compared with P14 CD8+T cells present in 
the spleen. Therefore CD8+T cells from the same source when introduced into 
the PEC were less apoptotic and more memory like when compared to those 
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which were introduced into the spleen. Thus, the in vivo PEC environment was 
not only promoting survival of CD8+T cells but selectively retained cells 
expressing memory markers.  
I reasoned that another possibility for the observation of fewer apoptotic 
cells in the PEC environment could be due to enhanced phagocytic clearance of 
pre-apoptotic T cells. If, for example, there were more apoptotic cell-scavenging 
phagocytes in the PEC than in the spleen, cells in early stages of apoptosis 
might be quickly scavenged and removed from the system. To test this possibility 
I adoptively transferred P14 CD8+T cells into a congenic host which was 
subsequently infected with LCMV. Nucleotides released by apoptotic cells can be 
recognized by phagocytic cells to promote apoptotic cell clearance (169). 
Apyrase, an enzyme which hydrolyses  nucleoside tri phosphates, can be used 
to prevent phagocytic clearance of apoptotic cells (169). Thus, by using Apyrase 
to block phagocytic uptake of apoptotic cells I questioned whether enhanced 
phagocytic clearance in the PEC tissue environment was contributing to tissue-
dependent apoptotic differences. At day 8 post infection mice were treated with 
Apyrase or succinate buffer control for 6 hours, following which splenocytes and 
PEC were isolated. Virus-specific CD8+T cells in the PEC and spleen of Apyrase-
treated mice were, as expected, more apoptotic when compared to the control 
group (Figure III-29), thus providing evidence that Apyrase inhibited phagocytic 
clearance. However, virus-specific, apoptosis-resistant CD8+T cells were still 
enriched in the PEC as compared to spleen in the Apyrase-treated group (Figure 
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III-29). This suggests that enhanced phagocytic clearance was not a major 
contributor to tissue-dependent differences in CD8+T cell apoptosis.           
G. Potential factors promoting CD8+T cell survival in the in vivo PEC 
environment 
Overall my results indicate that enhanced survival of CD8+T cells in the 
non-lymphoid tissues was a consequence of enrichment of this niche by cells 
which had an apoptosis-resistant antigenic and transcription factor phenotype. 
Furthermore, I show that apoptosis-resistant CD8+T cells may preferentially 
migrate into the non-lymphoid tissue where they will be stably maintained due to 
a yet undefined protective factor, that I have not been able to clearly resolve. 
Some preliminary experiments suggest that there may be some cytokines, co- 
stimulatory factors and cell types which might be actively promoting CD8+T cell 
stability in the non-lymphoid tissues. 
IL-7 is a cytokine belonging to common γ chain family of cytokines and is 
known to mediate survival and self-renewal of memory CD8+T cell populations 
(70, 71). IL-7 therapy during contraction of the immune response enhances the 
generation of memory CD8+T cells (170). IL-7 signaling induces STAT5 
phosphorylation, which is known to be associated with survival of effector and 
memory CD8+ T cells (118, 119). I questioned whether virus-specific CD8+T cells 
in the PEC had higher STAT5 phosphorylation when compared to the spleen 
counterparts in response to IL-7. Day 8 LCMV-infected MACS-sorted CD8+T 
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cells were stimulated directly ex-vivo with IL-7 for multiple time points and then 
stained intracellularly to identify STAT5 phosphorylation. As shown in Figure III-
30, I found that a higher proportion of virus-specific CD8+T cells in the PEC 
exhibited STAT5 phosphorylation in response to IL-7 directly ex-vivo as 
compared to the spleen. The expression level of pSTAT5 was also higher in 
virus-specific CD8+T cells in the PEC when compared to spleen, as shown by the 
MFI in Figure III-30. STAT5 signaling  activates Akt, which can inhibit apoptosis 
and promote cell survival (171, 172). Thus IL-7 mediated induction of STAT5 
phosphorylation may promote survival of CD8+T cells in the PEC environment. 
          CD27 is a co-stimulatory receptor, and stimulation through CD27 requires 
the presence of its co-stimulatory ligand CD70, which is expressed on dendritic  
cells, B cells, and activated CD4 and CD8 T cells. A study by another group 
showed that blocking CD70-CD27 co-stimulation during acute LCMV infection 
decreased the CD8+T cell response and the IL-7Rα expression on virus-specific 
CD8+T cells (173). Therefore, I stained total PEC and spleen leukocytes for CD70 
at day 9 post-LCMV infection. As shown by the overlay and MFI in figure III-31, I 
found that at day 9 post-LCMV infection total PEC leukocytes had a higher 
expression of CD70 as compared to spleen leukocytes. Thus, sustained CD27 
stimulation due to continued presence of CD70-expressing cells in the PEC 
environment might promote survival of virus-specific CD8+T cells.    
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Survival and proliferation of CD8+T cells can also be influenced by other 
cell types present in the tissue environment. CD4+T cell help has been shown to 
be important for survival, maintenance and generation of functional memory 
CD8+T cells (34-36)(174), and the absence of CD4+T cells decreased the 
proportion and survival of CD8+T cells at tissue effector sites (175, 176). I 
questioned whether CD4+T cells in the non-lymphoid tissues were also resistant 
to apoptosis during resolution of the immune response. At day 8 post-LCMV 
infection, lymphoid (spleen, inguinal lymph nodes, mesenteric lymph nodes) and 
non-lymphoid (fat-pad, PEC) tissues were harvested and stained directly ex-vivo 
for Annexin V. CD44hi CD4+T cells in the non-lymphoid tissues reacted much less 
with the apoptotic marker Annexin V compared to the lymphoid organs (Figure 
III-32). Day 8 LCMV-infected CD44hi CD4+T cells from non-lymphoid tissues were 
also less TUNEL reactive compared to lymphoid organs (data not shown), further 
confirming stability of CD4+T cells in the non-lymphoid tissues. Therefore, similar 
to CD8+T cells, CD4+T cells were also less apoptotic in the non-lymphoid tissues. 
I explored the possibility of CD4+T cells promoting CD8+T cell survival in 
the PEC by performing some additional studies. To track virus-specific CD4+T 
cell responses I adoptively transferred transgenic LCMV GP61 epitope-specific 
CD4+T cells (SMARTA) into a C57BL/6 congenic host, which was subsequently 
infected with LCMV. As shown in Figure III-33, at day 9 and day 15 post-LCMV 
infection a higher proportion of activated virus-specific CD4+T cells were present 
in the PEC relative to the spleen. Moreover, when stimulated with cognate 
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peptide virus-specific CD4+T cells in the PEC made much more IL-2 than those 
in the spleen (Figure III-33). IL-2 is a T cell growth factor and, while it can 
promote AICD of T cells under some circumstances,  IL-2 therapy during 
contraction of the immune response has been shown to increase CD8+T cell 
proliferation and survival (76). Earlier studies in mice lacking the IL-2 gene 
showed no role of IL-2 in regulating in vivo T cell responses to LCMV or VACV 
(177). However, these studies were confounded by presence of autoimmune and 
inflammatory conditions due to defective Treg function (178). Subsequent studies 
in which IL-2R deficient T cells were present in a wild type environment showed 
that both primary and secondary CD8+T cell responses are affected in absence 
of IL-2 signaling during LCMV infections (77, 78). Therefore, higher proportions of 
virus-specific CD4+T and CD8+T cells in the PEC are capable of making IL-2, and 
this could be another factor in the enhanced survival of CD8+T cells seen in the 
PEC environment. CD4+T cell help to CD8+T cells can be direct by providing 
cytokines and co-stimulation or indirect by activating APC. I found that CD8+T 
cell apoptosis in the PEC trended higher at day 8 post-LCMV infection in mice 
depleted of CD4+T cells at day 6 post infection (18.1±5.7% TUNEL+ in control 
mice vs 25.2±3.8% TUNEL+ in CD4 depleted mice) but no change was observed 
in the spleen (34.3±1.2% TUNEL+ in control mice vs 35.1±2.4% TUNEL+ in CD4 
depleted mice). Thus, the increased proportion of IL-2-producing CD4+T cells in 
the PEC environment could account for some of the increased resistance to 
apoptosis of virus-specific CD8+T cells in the PEC. IL-2 signals are transduced 
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by high-affinity IL-2R, which is comprised of CD25 (IL-2Rα), CD122 (IL2Rβ) and 
CD132 (common γ chain). CD25 expression is uniformly down-regulated in virus-
specific CD8+T cells during resolution of the immune response (81). However, the 
intermediate affinity IL-2R comprising of CD122 and CD132 is sufficient for 
responsiveness to IL-2 and IL-15 (179). I compared CD122 expression on virus-
specific CD8+T cells during the resolution and memory phase of the immune 
response. As shown in Figure III-34, I found a modest increase in the proportion 
of virus-specific CD8+T cells expressing CD122 in the PEC at day 9 post-LCMV 
infection compared to spleen, and this difference was enhanced at day 30 post-
LCMV infection. Expression of CD122 on a per-cell basis (as shown by MFI) was 
also increased in virus-specific CD8+T cells in the PEC compared to the spleen 
(Figure III-34). This might allow for IL-2- and IL-15-mediated CD8+T cell survival 
in the PEC environment. Overall these results indicate that decreased CD4+T cell 
apoptosis and their enhanced ability to produce IL-2 in the non-lymphoid tissues 
might be another factor promoting stability of CD8+T cells in the peripheral tissue 
environment. 
H. Discussion to Chapter III 
T cells persist at high frequencies in non-lymphoid tissues after resolution 
of the immune response, and these T cells are uniquely geared to produce   
effector cytokines (128, 129, 131, 132). The presence of memory T cells at non-
lymphoid tissue sites is critical for protection against secondary virus challenge 
(133, 137, 138, 161). Our lab has previously shown that during and after silencing of 
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the immune response, LCMV-specific CD8+T cells in non-lymphoid tissues are 
more resistant to apoptosis than those in the lymphoid organs (139). This 
differential in apoptosis could account for persistence of long-lived virus-specific 
memory CD8+T at high frequencies in the non-lymphoid tissues, serving as 
frontline defense against secondary virus challenge.  
          The studies performed in this chapter reveal the mechanisms underlying 
tissue-dependent differences in CD8+T cell apoptosis. I have shown here that 
higher proportions of virus-specific CD8+T cells in the non-lymphoid tissues 
expressed surface markers that correlated with an apoptosis-resistant 
phenotype. CD8+T cells which are IL-7Rhi and KLRG-1lo are thought to 
preferentially become memory cells (27, 72, 74), and these were found in higher 
proportions in non-lymphoid tissues (Figure III-7 and 8). IL-7 is important for 
survival and homeostatic proliferation of memory CD8+T cells (170). IL-7 signaling 
induces STAT5 phosphorylation, which is known to be associated with survival of 
effector and memory CD8+ T cells (118, 119). I found that a higher proportion of 
virus-specific CD8+T cells in the PEC exhibited STAT5 phosphorylation in 
response to IL-7 directly ex-vivo as compared to the spleen counterparts (Figure 
III-30). Though I have not directly tested IL-7 cytokine levels in PEC, IL-7 is 
constitutively produced by many cell types, and it is possible that stromal cells in 
the PEC environment might produce high amounts of IL-7, thereby  promoting 
optimal  survival of virus-specific CD8+T cells. I found that a higher proportion of 
virus-specific CD8+T cells in the PEC expressed CD27, which were less 
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apoptotic (Figure III-9). It has also been shown that CD27 sustains survival of 
virus-specific CD8+T cells in the non-lymphoid tissues by inducing autocrine IL-2 
production (85). Stimulation through CD27 requires the presence of its co-
stimulatory ligand CD70, and I found that at day 9 post-LCMV infection total PEC 
leukocytes had a higher expression of CD70 as compared to spleen leukocytes 
(Figure III-31). Thus, sustained CD27 stimulation due to continued presence of 
CD70-expressing cells in the PEC environment might promote survival of virus-
specific CD8+T cells. The collagen binding α1β1 integrin VLA-1 has been shown 
to be important in maintenance and survival of influenza A virus-specific CD8+T 
cells in lungs (180). However, I did not find VLA-1 to be highly expressed on 
LCMV-specific CD8+T cells in the PEC or spleen, suggesting that different 
mechanisms might regulate tissue-dependent survival in different tissues and 
during different viral infections. 
                I also explored the possibility of CD4+T cells promoting CD8+T cell 
survival in the PEC. Similar to CD8+T cells, CD4+T cells in the non-lymphoid 
tissues resisted apoptosis during resolution of the immune response to LCMV 
(Figure III-32). Furthermore, I found that a higher proportion of virus-specific 
CD8+T cell and CD4+T cells in the PEC are capable of making IL-2 (Figure III-11 
and 33), and this could be another factor in the enhanced survival of CD8+T cells 
seen in the PEC environment. However, I was unable to show the presence of 
IL-2 in the PEC environment directly ex-vivo by ELISA assays at day 7 post- 
LCMV infection. The inability to detect IL-2 could have been due to extremely low 
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levels of free IL-2 present in the tissue environment during resolution of the 
immune response. However, I also found that depleting CD4+T cells during 
resolution of the immune response modestly increased CD8+T cell apoptosis in 
the PEC but no change was observed in the spleen. Thus, increased resistance 
to apoptosis of virus-specific CD8+T cells in the PEC may be accounted by the 
increased proportion of IL-2-producing CD4+T cells in the PEC environment. 
Higher proportion of virus-specific CD8+T cells in the PEC expressed CD122 
(IL2Rβ) (Figure III-34) which might allow for IL-2- and IL-15- mediated CD8+T cell 
survival in the PEC environment if trace levels of these cytokines were made.  
        Initially I had performed experiments with mice immunized with serum-
containing LCMV stocks. I found that in in vitro assays CD4+T cells from the PEC 
but not the spleen responded strongly to serum (Figure III-35), thereby inducing 
IL-2 production that contributed to CD8+T cell survival in the PEC but not the 
spleen. Serum-free LCMV stocks were thus used for the experiments in the 
current study. Since CD4+T cells in the PEC had a dramatic response to serum 
antigen, we can speculate that a similar response to limited amounts of viral 
antigen in the PEC might promote CD4+T cell dependent CD8+T cell survival in 
the PEC. Influenza virus-derived antigens are known to be presented for a 
prolonged period in the lung after apparent resolution of infection (181), and  
whether similar persistence of LCMV antigen contributes to T cell survival is not 
clear. I also found that tissue-dependent differences in CD8+T cell apoptosis 
persisted even if the peritoneal cavity was not the initial site for antigen delivery. 
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In mice challenged with LCMV via i.v route the influx of activated CD8+T cells in 
the PEC was decreased, but, CD8+T cells in the PEC were still more resistant to 
apoptosis as compared to the spleen (10.1% Annexin V+ CD44hi CD8+T in the 
PEC vs 43.4% Annexin V+ CD44hi CD8+T in the spleen). 
Transcription factors can regulate CD8+T cell effector-memory fate 
decisions. I found that a higher proportion of CD8+T cells in the PEC express 
high amounts of TCF-1, LEF-1 and EOMES (Figure III-15,16,17), which are 
transcription factors known to correlate with T cell memory potential. By using the 
Tcf7-/- mice I showed that TCF-1 promoted survival of CD8+T cells in the non-
lymphoid tissues during resolution of the immune response. Moreover, by day 30 
post-LCMV infection nearly 100% of virus-specific CD8+T cells in the PEC were 
TCF-1 positive (Figure III-14) as compared to 61% IL-7Rhi KLRG-1lo (MPEC) 
(Figure III-8), suggesting that increased survival in non-lymphoid tissues was not 
simply due to presence of a higher proportion of MPECs. Expression of TCF-1 
can be modulated by Wnt ligands and by TCR and cytokine signals (105, 182, 183). 
It has been suggested that Wnt proteins might induce TCF-1-Eomes-IL2Rβ axis 
to induce cytokine responsiveness in memory CD8+T cells (105).  However, I did 
not observe significant differences in the expression of the canonical WNT 
signaling target Axin2 (data not shown) in T cells from the PEC relative to spleen, 
raising the possibility that TCF-1 has a Wnt-independent function in promoting 
memory CD8+T cell survival in the non-lymphoid tissues. How do virus-specific 
CD8+T cells maintain higher TCF-1 expression in the PEC? The PEC 
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environment is enriched in macrophages and dendritic cells, which in vitro are 
known to produce Wnt5a, which induces the non-canonical Wnt pathway (184). 
Alternatively, it is possible that TCF-1-expressing cells might preferentially 
populate the peritoneal cavity. Future studies will need to define the underlying 
mechanism for the biased recruitment and/or maintenance of TCF-1hi cells in 
non-lymphoid tissues.  
T cells migrate into tissue effector sites post-activation to eliminate foreign 
antigens, and I provide evidence that non-apoptotic CXCR3+CD8+T cells 
accumulated in the lymph nodes if their egress was blocked by FTY720 
treatment. CXCR3+CD8+T cells are known to migrate in response to IFNγ-
inducible chemokines CXCL9 and CXCL10. CXCL9 and CXCL10 are produced 
by activated macrophages and DC’s, and I found that the PEC environment had 
higher expression of these chemokines. Thus, during resolution of the immune 
response non-apoptotic memory phenotype CD8+T cells likely migrate 
preferentially into non-lymphoid tissues. This trafficking pattern, in conjunction 
with tissue-intrinsic differences in promoting cell survival, provides an attractive 
mechanism for promoting long-lived immunity at non-lymphoid tissues. 
I provide evidence that multiple mechanisms account for tissue-dependent 
differences in CD8+T cell apoptosis seen during resolution of the immune 
response (Figure III-36). These mechanisms would work in conjunction to 
promote survival and overall maintenance of CD8+T cell populations in the non-
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lymphoid tissues. The presence of functional long-lived memory CD8+T cells at 
non-lymphoid tissue effector sites would ensure a productive response on 
encounter with the antigen providing protection against secondary virus 
challenge.  
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CHAPTER IV: BLIMP-1 SUPPRESSES CD25 AND CD27 EXPRESSION TO 
NEGATIVELY REGULATE CD8+T CELL MEMORY DIFFERENTIATION 
In response to a virus infection, CD8+T cells proliferate and differentiate 
into effector cells that eradicate the pathogen. The population of effector CD8+T 
cells generated during an immune response is heterogeneous; the majority of 
effector cells die, whereas a small population survive and become memory cells. 
Transcriptional profiling of effector and memory CD8+T cells in both acute and 
chronic virus infection has recently provided insight into the gene expression 
programs characterizing distinct cell subsets (89). Nonetheless, the precise 
mechanisms by which these transcriptional programs are established and 
maintained during CD8+T cell differentiation remain largely unknown. 
The transcription factor Blimp-1 (encoded by Prdm1 gene) drives CD8+T 
cell differentiation towards short-lived effector cells at the expense of memory 
precursors (94, 95). Although Blimp-1 is known to regulate a number of target 
genes mediating plasma cell differentiation (90), only a few targets of Blimp-1 in 
CD8+T cells have been identified. One recent study has shown that Blimp-1 
directly regulates expression of the DNA-binding inhibitor Id3 and thereby 
contributes to the development of short-lived effector T cells (97). However, more 
global information on the targets of Blimp-1 in CD8+T cells is currently lacking. 
In this study I wanted to identify the mechanisms by which Blimp-1 
regulates differentiation of effector-memory CD8+T cells. Preliminary genome-
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wide ChIP-sequencing studies done by my collaborator Dr. HyunMu Shin in the 
lab of Dr. Leslie J. Berg identified novel Blimp-1 target genes.  During contraction 
of the CD8+T cell response, when viral antigens are no longer present, cytokine 
stimulation and/or co-stimulatory signals become critical for T cell survival and 
memory development (52, 67). Therefore, to address the functional importance of 
specific Blimp-1 target genes in CD8+ T cells, I chose to focus on cytokine and 
co-stimulatory receptors, particularly CD25 (IL-2Rα) and CD27, as these are 
known to be critical in regulating T cell function and differentiation. In this study I 
show that CD25 and CD27 expression is dysregulated in Prdm1-/- T cells 
responding to LCMV infection, that T cells expressing CD25 and CD27 
preferentially survive during acute viral infection, and that silencing of IL-2Rα 
and/or Cd27 in Blimp-1-deficient CD8+T cells decreases the magnitude of the 
virus specific CD8+T cell response. Furthermore, by using genome-wide ChIP-
sequencing analysis our collaborating group identified IL-2Rα (CD25) and CD27 
genes as direct targets of Blimp-1. At the peak of the anti-viral response, but not 
earlier, Blimp-1 recruited the histone modifying enzymes G9a (methyl 
transferase) and HDAC2 (Histone deacetylase 2) to the Il2rα and Cd27 loci, 
thereby repressing expression of these genes. Therefore, we found that Blimp-1 
suppresses CD25 and CD27 expression by inducing histone modifications to 
negatively regulate CD8+T cell differentiation. These studies were done in 
collaboration with Dr. HyunMu Shin and Dr. Leslie J. Berg, and are a part of the 
manuscript titled “Epigenetic Modifications Induced by Blimp-1 Regulate CD8+T 
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Cell Memory Progression during Acute Virus Infection” (Immunity 39, 1-15, 
October 17, 2013). 
A. Increased CD8+T cell response and memory development in Blimp-1- 
deficient mice 
To investigate the role of Blimp-1 in regulating CD8+T cell responses 
during a virus infection, we used mice carrying a conditional Prdm1 allele in 
which exon 5 is flanked by loxP sites (159). This line was crossed to Cd4-cre+ 
transgenic mice, thereby deleting Prdm1 in all αβ T cells (referred to as Prdm1-/-), 
and differed from those previously used in studies of Blimp-1 function in B and T 
lymphocytes (185, 186). We used Cd4-cre+ littermate mice as wild type controls 
(referred to as WT) for our studies. Since the conditional knockout (CKO) line 
generated by us was different from previously used lines we had to verify that 
these Blimp-1 CKO mice had a phenotype similar to what has been previously 
reported. As previously reported (185, 187), I  did not detect any changes in the 
proportion of lymphocytes in various lymphoid organs, although naïve Prdm1-/- 
mice had a higher proportion of CD44hi CD4+ and CD8+T cells when compared to 
WT controls (data not shown). I also tested CD8+T cell response in the Prdm1-/- 
mice during an acute LCMV infection. Consistent with previous studies (94, 96), I 
found that there was a higher absolute number of CD8+T cells in Prdm1-/-  mice at 
day 7 post-LCMV infection (Figure IV-1). I also found a marked increase in the 
proportion of activated CD44hi CD8+T and LCMV-specific NP396+ and GP33+ 
CD8+T cells in Prdm1-/- at day 7 after LCMV Armstrong infection (Figure IV-1) 
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and these differences were also seen at day 14 post infection (data not shown). 
Blimp-1 deficiency leads to generation of higher proportion of MPEC CD8+T cells 
(KLRG-1lo IL-7Rαhi; (94)), and as shown in figure IV-2, I also found a higher 
proportion of LCMV-specific NP396+CD8+T cells with a MPEC phenotype in the 
Prdm1-/- mice at day 7 and day 14 post infection. Therefore, the phenotype seen 
in Prdm1-/- mice during acute LCMV infection was similar to previous reports. The 
transcription factor EOMES promotes persistence of memory CD8+T cells (110). 
Since, a higher proportion of Blimp-1-deficient T cells had a memory phenotype I 
compared EOMES expression in virus-specific T cells from Prdm1-/- and WT 
mice. As shown in Figure IV-3, I found that a higher proportion of LCMV-specific 
NP396+ CD8+T cells from Prdm1-/- mice expressed EOMES compared to WT 
controls at days 7 and 14 post infection. The expression level of EOMES was 
also higher in virus-specific CD8+T cells in the Prdm1-/- mice when compared to 
WT controls, as shown by the MFI in Figure IV-3. Increased magnitude of the 
CD8+T cell response in Prdm1-/- mice during an acute LCMV infection could have 
been due to defective viral clearance. Therefore, I enumerated viral-titers in 
Prdm1-/- by plaque assays at day 4, 7 and 8 post-LCMV infection. As shown in 
Figure IV-4, viral clearance in the spleen of Prdm1-/- mice was similar to WT 
controls, indicating that the increased magnitude of the CD8+T cell response to 
LCMV in Prdm1-/- mice was not due to impaired viral clearance. 
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B. Increased proliferation and decreased CD8+T cell apoptosis in the Blimp-
1-deficient mice during resolution of the immune response 
Blimp-1 deficiency in CD8+T cells leads to an increased magnitude of the CD8+T 
cell response. This could have been due to increased proliferation or decreased 
apoptosis of T cells due to Blimp-1 deficiency. A previous study has shown that 
Blimp-1-expressing virus-specific CD8+T cells had decreased proliferative 
capabilities in vitro (94).To test whether Blimp-1 deficiency leads to increased T 
cell proliferation in vivo, day 7 LCMV infected Prdm1-/- and WT control mice were 
injected i.p with BrdU and sacked after 11 hours. I found that a higher proportion 
of LCMV-specific GP33+CD8+T cells from Prdm1-/- mice incorporated BrdU 
compared to WT controls (Figure IV-5). Therefore, enhanced proliferation of T 
cells contributes to the increased magnitude of the CD8+T cell response seen in 
Blimp-1-deficient mice. Alternatively, decreased T cell apoptosis can also 
contribute to increased CD8+T cell responses. To test whether Blimp-1-deficient 
CD8+T cells were less apoptotic during resolution of the immune response, 
splenocytes from day 9 LCMV-infected Prdm1-/- and WT control mice were 
cultured directly ex-vivo for 5 hours. As shown by decreased TUNEL reactivity, 
CD44hi CD8+T cells from Blimp-1-deficient mice were less apoptotic as compared 
to WT controls (Figure IV-6). Decreased apoptosis can result from the presence 
of pro-survival factors such as Bcl-2, which has been shown to be important in 
counteracting the effects of pro-apoptotic Bim, thereby allowing for survival of 
cells during contraction of the immune response (54). In  
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accord with the decreased apoptosis, a higher proportion of LCMV-specific 
CD8+T cells in the Prdm1-/- mice expressed Bcl-2 at day 7 post infection when 
compared to WT controls (Figure IV-7). Therefore, these results show that the 
increased magnitude of the CD8+T cell response seen in the Blimp-1-deficient 
mice was due to a combined effect of increased proliferation and decreased T 
cell apoptosis. 
C. Blimp-1 suppresses cytokine responsiveness of CD8+T cells at the peak 
of the anti-viral response 
Since CD8+T cells from the Prdm1-/- mice had increased proliferation and 
survival, I questioned whether differential cytokine responsiveness in WT versus 
Prdm1-/- T cells contributes to altered T cell survival and/or proliferation. To 
address this question I isolated CD8+T cells from WT and Prdm1-/- mice infected 
with LCMV Armstrong at day 7 (peak expansion) post infection. Sorted CD8+T 
cells were then labeled with CFSE, and cultured in vitro for 2 days with a panel of 
cytokines (Figure IV-8). As shown in Figure IV-8, Prdm1-/- CD8+T cells had 
enhanced proliferation in response to the cytokines IL-2, IL-12, and IL-15 at day 
7 post infection when compared to WT controls. This suggested that Blimp-1 
suppresses cytokine responsiveness of CD8+T cells at the peak of the anti-viral 
response, and that the ability of Blimp-1-deficient T cells to respond to certain 
cytokines during the peak and resolution of the immune response might 
contribute to their enhanced survival and/or proliferation. 
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D. Blimp-1 regulates CD25 expression in virus-specific CD8+T cells during 
anti-viral immune response 
Because the cytokine responsiveness of T cells during viral infections can 
be regulated by the modulation of cytokine receptor expression (74, 80), I 
questioned whether Blimp-1 might function to suppress cytokine receptor 
expression during the anti-viral immune response. I chose to focus on CD25, 
which is the high affinity IL-2Rα for the following reasons: a) Blimp-1-deficient T 
cells were more responsive to IL-2 at the peak of the immune response when 
compared to WT controls (Figure IV-8), b) IL-2 is a cytokine which is known to 
promote survival and proliferation of T cells, c) genome wide ChIP-sequencing 
analysis performed by our collaborating group identified CD25 as a potential 
target of Blimp-1. Therefore, to test whether CD25 expression was dysregulated 
in CD8+T cells lacking Blimp-1, I infected Prdm1-/- and WT mice with LCMV and 
analyzed virus-specific CD8+T cells for CD25 expression at days 7-9 post 
infection. Consistent with the increased responsiveness to IL-2, approximately 
twice as many LCMV-specific GP33+ and NP396+ CD8+T cells from Prdm1-/- 
mice expressed CD25 when compared to WT controls (Figure IV-9). As shown in 
Figure IV-9, compared to WT controls the Prdm1-/- T cells continued to have 
proportionally higher CD25 expression until day 9 post infection, although the 
overall proportion of CD25+CD8+T cells diminished dramatically after day 7. 
Since the conditional Blimp-1-deficient mice used in this study lacked Blimp-1 in 
both CD4+ and CD8+T cells, I wanted to confirm that dysregulated CD25 
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expression due to Blimp-1 deficiency was CD8+T cell intrinsic and not due to the 
presence of Blimp-1-deficient CD4+T cells in the environment. To address this 
question I adoptively transferred P14 TCR transgenic WT or Prdm1flox/flox x 
GzmB-cre+ CD8+T cells (in which Cre expression was under the control of the 
human Granzyme B promoter (94), therefore activated CD8+T cells will become 
Blimp-1 deficient) into a WT host which were then infected with LCMV. I found 
that at day 9 post infection a higher proportion of virus-specific P14 Prdm1flox/flox x 
GzmB-cre+ CD8+T cells expressed CD25 compared to WT controls (Figure IV-
10), supporting the idea that this function of Blimp-1 was intrinsic to CD8+T cells. 
To further confirm the inverse correlation between Blimp-1 and CD25 expression, 
I infected Blimp-1 GFP mice in which GFP expression is under the control of 
Prdm1 promoter (187), thereby allowing us to track Blimp-1-expressing cells. As 
shown in Figure IV-11, a higher proportion of CD25-expressing CD8+T cells were 
present in the Blimp-1lo subset as compared to Blimp-1hi subset at days 7 and 9 
post infection. Therefore, CD25 expression inversely correlated with Blimp-1 
expression. These data together indicate that Blimp-1 represses CD25 
expression at late stages during the anti-viral CD8+T cell response. 
Recent studies have demonstrated that CD25 expression during the early 
expansion phase of the antiviral CD8+T cell response is critical in regulating cell 
fate in that CD25hi cells become short-lived effector cells (80, 91). To confirm 
these findings I compared expression of memory markers IL-7R and CD62L on 
CD25hi- and CD25lo-CD44hi CD8+T cells at day 5 post-LCMV infection.  
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Consistent with previous findings, I also observed that high CD25 expression at 
day 5 post-infection correlated with decreased IL-7Rα and CD62L expression 
(Figure IV-12); further, at this stage of the response, cells expressing higher 
Blimp-1 also expressed more CD25 (Figure IV-11) (80). These data indicate that 
strong IL-2R signaling during the early stage of the antiviral CD8+T cell response 
promotes the development of short-lived effector cells. However, I considered 
whether the role of IL-2R signaling might be different at the later stage of the 
response, at which time CD8+T cells undergo attrition. In support of this 
possibility, I found that at day 9 post infection, CD25 expression on CD8+ T cells 
positively correlated with IL-7Rα and CD62L expression (Figure IV-12), indicating 
that, compared to the CD25lo population, the CD25hi population at this stage was 
enriched with memory precursor cells.  
Although during resolution of the immune response CD25hi CD8+T cells were 
enriched with memory precursor cells, I wanted to directly test whether 
differences in CD25 expression on virus-specific CD8+T cells are associated with 
differences in T cell survival and/or persistence. To address this question 
splenocytes from P14 TCR transgenic mice were adoptively transferred into a 
congenic host which was subsequently infected with LCMV. CD25hi and CD25lo 
P14 TCR transgenic CD8+T cells were then sorted from mice at day 7 after 
LCMV infection, as shown in the schematic in Figure IV-13. Sorted T cells were 
adoptively transferred into infection-matched congenic hosts, and the number of 
P14+ T cells was assessed at day 15 post infection (8 days post transfer). As 
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shown in Figure IV-13, I found that a higher proportion and absolute number of 
virus-specific CD25hi CD8+ T cells than of CD25lo transferred cells survived in the 
infection-matched host. These results indicate that, at day 7 post-infection, CD25 
expression on virus-specific CD8+T cells correlated with their enhanced survival 
and/or persistence. To determine whether enhanced proliferation contributed to 
this effect, I injected LCMV-infected WT and Prdm1-/- mice with BrdU at day 7 
post-infection and analyzed LCMV-specific GP33+ CD8+T cells 12 hour later for 
BrdU incorporation, which is indicative of proliferation. A higher proportion of 
CD25hi T cells than of CD25lo cells exhibited BrdU incorporation in the WT and 
Prdm1-/- mice (Figure IV-14). Therefore, a higher proportion of CD25 expressing 
cells are present in the Blimp-1-deficient mice, which I show here are more 
proliferative during resolution of the immune response. Though overall as shown 
in Figure IV-5, Blimp-1-deficient CD8+T cells were more proliferative when 
compared to WT controls irrespective of their CD25 expression. The ability of 
virus-specific CD8+T cells to produce multiple cytokines, such as IFNγ, TNF and 
IL-2, simultaneously during viral infection is a primary indicator of their functional 
capacity. I questioned whether CD25hi cells represented a functional memory 
pool compared to CD25lo populations. As shown in Figure IV-15, I found that in 
response to ex-vivo LCMV peptide stimulation at day 8 post infection, a higher 
proportion of CD25hi CD8+T cells than of CD25lo CD8+T cells produced IFNγ and 
IL-2, correlating high expression of CD25 with a functional memory T cell 
response. Overall these data indicate that Blimp-1 represses CD25 expression at  
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late stages during antiviral CD8+T cell response, and following the peak of the 
CD8+T cell response to LCMV, higher expression of CD25 correlates with 
enhanced survival and/or persistence of virus-specific T cells. 
E. Blimp-1 regulates CD27 expression in virus-specific CD8+T cells during 
anti-viral immune response 
Apart from cytokine receptors, co-stimulatory molecules are known to be critical 
for the clonal expansion and survival of CD8+T cells (67). CD27, a co-stimulatory 
molecule of the TNF receptor family promotes memory generation and survival of 
CD8+T cells (67). Genome-wide ChIP-sequencing analysis performed by Dr. 
HyunMu Shin identified CD27 as a potential target of Blimp-1. Therefore, to test 
whether CD27 expression was dysregulated in CD8+T cells lacking Blimp-1, I 
infected Prdm1-/- and WT mice with LCMV and analyzed virus-specific CD8+T 
cells for CD27 expression at days 7.5-9 post infection. As shown in Figure IV-16, 
at day 7.5 post-LCMV infection a higher proportion of LCMV-specific GP33+ and 
NP396+ CD8+T cells from Prdm1-/- mice expressed CD27 when compared to WT 
controls, and the differences became more apparent by days 8 and 9 post 
infection. Since the conditional Blimp-1-deficient mice used in the study lacked 
Blimp-1 in both CD4+ and CD8+T cells, I wanted to confirm that dysregulated 
CD27 expression due to Blimp-1 deficiency was CD8+T cell intrinsic and not due 
to the presence of Blimp-1-deficient CD4+T cells in the environment. To address 
this question I adoptively transferred P14 TCR transgenic WT or Prdm1flox/flox x 
GzmB-cre+ CD8+T cells into a WT host which were then infected 
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with LCMV. I found that at day 9 post-infection a higher proportion of virus-
specific P14 Prdm1flox/flox x GzmB-cre+ CD8+T cells expressed CD27 compared to 
WT controls (Figure IV-17), supporting the idea that this function of Blimp-1 was 
intrinsic to CD8+T cells. To further confirm the inverse correlation between Blimp-
1 and CD27 expression, I infected Blimp-1 GFP mice in which GFP expression is 
under the control of the Prdm1 promoter (187), thereby allowing us to track Blimp-
1-expressing cells. As shown in Figure IV-18, a higher proportion of CD27-
expressing CD8+T cells were present in the Blimp-1lo subset as compared to 
Blimp-1hi subset at day 9 post infection. Furthermore, CD27 expression on 
CD8+T cells was higher in the Blimp-1lo subset as compared to Blimp-1hi subset 
as represented by the MFI in Figure IV-18. Therefore, CD27 expression inversely 
correlated with Blimp-1 expression. These data together indicate that Blimp-1 
represses CD27 expression during the peak and resolution of the anti-viral 
CD8+T cell response. 
It has been previously shown that CD27-expressing CD8+T cells represent 
a functional memory pool (88). To confirm that CD27 expression on virus-specific 
CD8+T cells at day 9 post infection represents a subset enriched with memory 
precursor cells, I examined IL-7Rα expression on LCMV-specific CD8+T cells 
with varying CD27 expression. As shown in Figure IV-19, increasing amounts of 
IL-7Rα on LCMV-specific GP33+CD8+T cells correlated with increased CD27 
expression. Although during resolution of the immune response CD27hi CD8+T    
cells were enriched with memory precursor cells, I wanted to directly test whether 
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differences in CD27 expression on virus-specific CD8+T cells are associated with 
differences in T cell survival and/or persistence. To address this question 
splenocytes from P14 TCR transgenic mice were adoptively transferred into a 
congenic host which was subsequently infected with LCMV. CD27hi and CD27lo 
P14 TCR transgenic CD8+T cells were then sorted from mice at day 9 after 
LCMV infection, as shown in the schematic in Figure IV-20. Sorted T cells were 
adoptively transferred into infection-matched congenic hosts, and the number of 
P14+ T cells was assessed at day 16 post infection (7 days post transfer). As 
shown in Figure IV-20, I found that a higher proportion and absolute number of 
virus-specific CD27hi CD8+T cells than of CD27lo transferred cells survived in the 
infection-matched host. These results indicate that, during resolution of the 
immune response, CD27 expression on virus-specific CD8+T cells correlated with 
their enhanced survival and/or persistence.  
F. Sustained CD25 and CD27 expression contributes to the increased 
magnitude of Blimp-1-deficient CD8+T cell response 
So far I’ve shown that CD25 and CD27 expression was enhanced in 
Blimp-1-deficient CD8+T cells and that expression of CD25 and CD27 on CD8+T 
cells during resolution of the immune response correlates with a memory 
phenotype. The next question addressed was whether persistent CD25 and 
CD27 expression contributed to the increased magnitude of the Blimp-1-deficient 
CD8+T cell response. To address this question, we utilized small hairpin RNA 
(shRNA) silencing to diminish expression of CD25 and CD27 proteins in LCMV- 
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specific Prdm1-/- T cells. The generation of shRNA RV (Retrovirus) constructs 
and transduction of Prdm1-/- P14+ T cells was performed by Dr. HyunMu Shin in 
the lab of Dr. Leslie J. Berg. For these experiments, P14+CD90.1+ Prdm1flox/flox x 
GzmB-cre+ splenocytes were adoptively transferred into a congenic WT host and 
were activated in vivo by infection of recipient mice with LCMV. At day 5 post 
infection, P14+ T cells were isolated by cell sorting, stimulated in vitro with CD3 
and CD28 antibodies for 24 hours, infected with RV carrying shRNA to IL-2Rα 
and CD27, and then transferred into LCMV-infected (day 6 post-infection) 
recipient mice (Figure IV-21). As shown by GFP expression (RV vectors also 
expressed GFP, allowing us to track transduced T cells), we achieved similar 
transduction efficiencies for each of the RV constructs (Figure IV-21); in addition, 
each shRNA was able to reduce expression of the targeted gene (Figure IV-22). 
When analyzed at day 9 post infection, the proportion of Prdm1-/- CD8+T cells 
transduced with shCD25 or shCD27 was lower than that of cells transduced with 
the scrambled shRNA control (Figures IV-22). Moreover, silencing of both Il2rα 
and Cd27 further decreased the frequency of GFP+CD8+T cells (Figure IV-22), 
suggesting a non-redundant role of CD25 and CD27 in sustaining CD8+T cell 
responses. Overall, these results indicate that the increased magnitude and 
survival of CD8+T cells in Prdm1-/- mice was in part due to sustained expression 
of CD25 and CD27. 
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G. Blimp-1 directly represses Il2rα and Cd27 expression by recruiting 
histone-modifying enzymes to induce repressive chromatin modifications 
The following studies were performed by Dr. HyunMu Shin in the lab of Dr. 
Leslie J. Berg and are a part of the manuscript titled “Epigenetic Modifications 
Induced by Blimp-1 Regulate CD8+T Cell Memory Progression during Acute 
Virus Infection” (Immunity 39, 1-15, October 17, 2013). 
Transcriptional regulation by Blimp-1 has been extensively studied in B 
cells, leading to the identification of Myc, Pax5, Bcl6, Ciita, Spib, Id3, and Prdm1 
as direct Blimp-1 target genes (90). Substantially less is known about the direct 
targets of Blimp-1 in T cells, particularly CD8+T cells. To identify Blimp-1 target 
genes in CD8+T cells, Dr. HyunMu Shin performed genome-wide ChIP-seq 
analysis. Naïve CD8+T cells from OT-I TCR transgenic Rag1-/- mice were 
stimulated for 3 days in vitro in the presence of IL-2 to upregulate Blimp-1 (93). 
For identifying the genomic locations of Blimp-1 binding sites, chromatin was 
immunoprecipitated with Blimp-1 antibody and DNA was subjected to deep 
sequencing. Consistent with previous studies (94, 97), this analysis identified 
Prdm1,Id3, Bcl6, Pax5, Myc, and Ciita as having Blimp-1 binding sites in CD8+T 
cells. In addition, the study identified Il2rα, Cd27, Il2rb, Sell (Cd62l), Eomes, and 
Ccr6 as Blimp-1 targets. To further confirm the results of ChIP-seq analysis day 7 
LCMV-infected activated CD8+T cells were subjected to ChIP by Blimp-1 
antibody. He found that Blimp-1 bound to the Il2rα and Cd27 loci in WT CD8+T 
cells further supporting the conclusion that Blimp-1 binding to the Il2rα and Cd27 
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loci represses expression of CD25 and CD27, respectively, during the anti-viral 
CD8+T cell response. 
In previously characterized systems, Blimp-1 has been shown to mediate 
transcriptional repression by associating with histone-modifying enzymes (188-
191). Because there is differential histone modification between memory and 
effector CD8+ T cell subsets (192), we considered whether Blimp-1 might function 
in T cells to regulate histone lysine modification. To examine whether Blimp-1 
mediates the recruitment of histone-modifying enzymes G9a (methyltransferase) 
or HDAC2 (histone deacetylase 2) to Blimp-1 binding sites, Dr. HyunMu Shin 
isolated CD8+T cells from WT or Prdm1-/- mice at day 7 after LCMV infection. 
ChIP assays revealed that both G9a and HDAC2 were present at the Il2rα and 
Cd27 loci in WT CD8+T cells at day 7 post-infection and we did not detect any 
binding of G9a and HDAC2 in Prdm1-/- CD8+T cells, indicating that Blimp-1 is 
required for the recruitment of G9a and HDAC2 to these genes. Furthermore, Dr. 
HyunMu Shin could show that Blimp-1 induced a repressive chromatin state at 
Il2rα and Cd27 loci in CD8+T cells at the peak of the immune response to LCMV. 
Together, these findings demonstrate that Blimp-1 suppresses CD25 and CD27 
expression by inducing a repressive chromatin state at Il2rα and Cd27 loci in 
CD8+T cells at the peak of the response to LCMV infection. 
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H. Discussion to Chapter IV 
Blimp-1-deficient CD8+T cells have an enhanced capacity to differentiate 
into memory cells (94, 95). In this study, which was done in collaboration with Dr. 
HyunMu Shin and Dr. Leslie J. Berg, we have identified an important mechanism 
by which Blimp-1 association with histone-modifying enzymes suppresses Il2rα 
and Cd27 expression to regulate the overall magnitude of the virus-specific 
memory CD8+T cell response. Upon virus infection and T cell activation, co-
stimulatory signals, along with the inflammatory cytokine milieu, are key 
components leading to the generation of CD8+ effector and memory precursor T 
cells that together promote virus clearance and provide long-term protection 
against reinfection. After virus clearance, CD8+T cells down-regulate co-
stimulatory receptor and cytokine receptor expression (67, 80). After this process, 
the vast majority of the virus-specific effector population undergoes apoptosis 
(50), most likely as a result of cytokine deprivation and the lack of co-stimulatory 
signals. Our data indicate that CD25 (or CD27) has an impact on the small 
proportion of effector cells capable of long-term survival and provides an 
important signal to promote the survival of cells expressing the receptor in this 
specific subset. We propose that Blimp-1 normally functions to down-regulate 
cytokine receptor expression and thereby promotes the death of effector T cells. 
This mechanism would function in addition to the regulation of proliferation and 
survival genes by Blimp-1, as proposed previously (193).   
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Over the past decade, numerous studies have investigated the role of IL-2 
signaling in CD8+T cell activation and differentiation in response to virus 
infections (75). These studies showed that CD25 expression and the strength of 
IL-2R signaling during T cell priming influences the relative generation of effector 
versus memory CD8+T cells. Furthermore, in vivo administration of IL-2 during T 
cell contraction increases the size of the CD8+ memory pool (76). These data 
prompted us to investigate whether IL-2 receptor expression is regulated by 
distinct mechanisms at different stages of the anti-viral immune response, and 
further, whether the function of IL-2R signaling might also vary between T cell 
priming and T cell contraction. CD25 expression on CD8+T cells is rapidly 
induced during the early stage of viral infection, mediated by a combination of 
TCR and IL-2R signaling (75). During this early stage, cells expressing CD25 are 
destined to be short-lived effectors, in keeping with their high Blimp-1 expression 
(80, 94). Our data indicate that, at this time point, Blimp-1 expression is not able to 
override the positive signals promoting CD25 expression. In contrast, by day 7 
post-infection, CD25 expression is nearly absent on virus-specific cells, a change 
that is Blimp-1 dependent. We propose that after viral clearance and the 
cessation of IL-2 production, CD25 expression becomes susceptible to regulation 
by Blimp-1. It has been shown previously that Prdm1-/- mice consistently maintain 
higher proportions and numbers of memory CD8+T cells (94). Although we have 
not directly looked at later time points after viral infection, the transcription factor 
EOMES was upregulated in Prdm1-/- mice (Figure IV-3), consistent with our 
 
 141 
ChIP-seq analysis. CD8+T cells from Prdm1-/- mice were also more responsive to 
IL-15 stimulation (Figure IV-8). Therefore, it is likely that the EOMES and IL-15 
axis promotes the homeostatic proliferation and survival of the increased memory 
T cell pool in Prdm1-/- mice.  
In this study, we confirmed that CD25 and CD27 expression was 
significantly altered in Prdm1-/- CD8+T cells during the course of LCMV infection. 
Blimp-1 directly bound to the Il2rα locus, was required for recruitment of HDAC2 
and G9a to this gene, and was required for the repressive chromatin 
modifications seen at the Il2rα locus in CD8+T cells from day 7 LCMV-infected 
mice. Unlike that of Il2rα, the transcriptional regulation of Cd27 is not well defined 
in T cells. Although present on naive T cells, TCR stimulation leads to further up-
regulation of CD27 (194). The mechanisms leading to CD27 down-regulation are 
even more poorly characterized. Although ligation with CD70 or stimulation with 
phorbol myrsitate acetate (PMA) down-regulates CD27 expression (195, 196), the 
factors mediating this event are not known. Our work has provided evidence that 
Blimp-1 plays a key role in CD27 down-regulation following the peak of the anti-
viral CD8+T cell response. As with the Il2rα locus, Blimp-1 binds to Cd27 and 
recruits the histone-modifying enzymes, HDAC2 and G9a, leading to repressive 
modifications at this locus during CD8+T cell contraction. 
In the study highlighted in this chapter, I show that CD25 and CD27 
expression is decreased in Prdm1-/- T cells responding to LCMV infection, that T 
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cells expressing CD25 and CD27 preferentially survive during acute viral 
infection, and that silencing of Il2rα and/or Cd27 in Blimp-1-deficient CD8+T cells 
decreases the magnitude of the virus-specific CD8+T cell response. Our 
collaborating group identified Il2rα and Cd27 as direct targets of Blimp-1 with the 
use of deep-sequencing analysis of Blimp-1-bound DNA targets in CD8+T cells 
(ChIP-seq analysis). They could also show that at the peak of CD8+T cell 
expansion, but not early in infection, Blimp-1 binds to regulatory regions of Il2rα 
and Cd27 and recruits G9a or HDAC2 to promote repressive histone 
modifications at these loci. These data provide key insights into the mechanism 
by which Blimp-1 acts as an epigenetic regulator of target genes, thereby 
dictating the fate of CD8+ effector T cells (Figure IV-23). 
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CHAPTER V: THE TRANSCRIPTION FACTOR ROG/Zbtb32 NEGATIVELY 
REGULATES THE CD8+T CELL RESPONSE DURING ACUTE AND CHRONIC 
VIRAL INFECTION 
Upon recognition of the viral antigen CD8+T cells get activated and 
proliferate. Depending on the strength of the stimulus, cytokine milieu, and co-
stimulatory factors, a transcriptional program is initiated, governing the fate of 
effector T cells. Transcriptional profiling of effector and memory CD8+T cells in 
models of both acute and chronic virus infection has recently provided insight into 
the gene expression programs characterizing distinct cell subsets (89). ROG is a 
transcription factor which belongs to the POZ family of proteins (152). Most of the 
POZ family members are transcriptional repressors, and some of the well-known 
members of this family include PLZF (Promyelocytic leukemia Zn finger protein) 
and Bcl-6 (B cell lymphoma-6), and are known to play an important role in T cell 
function and differentiation. 
ROG is expressed in activated T and B cells, and in vitro studies have 
suggested that ROG negatively regulates T cell activation (152, 154, 155) (156). 
ROG-deficient mice have been generated and were shown to have no defect in 
mounting a Th1 immune response in an EAE induction model (156). Our current 
understanding of the function of ROG in regulating in vivo T cell responses is 
extremely limited. 
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The studies highlighted in this chapter have been done in collaboration 
with Dr. HyunMu Shin in the lab of Dr. Leslie J. Berg at UMMS, and initial studies 
carried out in their lab suggested that ROG is an early IL-2-induced gene. Since 
ROG is induced upon T cell activation, I questioned whether ROG was important 
in regulating CD8+T cell responses during acute and chronic LCMV infections. I 
found that upon acute infection with LCMV Armstrong, Zbtb32-/- mice 
accumulated higher proportions and numbers of virus-specific CD8+T cells, 
resulting in an increased number of memory cells. These defects were CD8+T 
cell intrinsic. I also examined the response of Zbtb32-/- mice to chronic infection 
with a high dose of LCMV Clone 13 and found that approximately two-thirds of 
Zbtb32-/- mice infected with high dose LCMV Clone 13 succumbed to this 
infection as early as day 9 post infection and also exhibited more severe immune 
pathology in the lung compared to WT mice. The higher frequency of IFNγ 
producing virus-specific CD8+T cells in Zbtb32-/- mice also resulted in enhanced 
viral control following LCMV Clone 13 infection. Thus, I could show that ROG 
plays a unique non-redundant role in negatively regulating CD8+T cell response 
and memory T cell generation during acute and chronic LCMV infection. 
A. ROG is expressed in virus-specific CD8+T cells during acute LCMV 
infection 
Several in vitro studies have shown that ROG is induced in T cells upon 
activation. Since I wanted to study the function of ROG in regulating in vivo T cell 
responses, I questioned whether ROG was induced in virus-specific CD8+T cells 
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upon infection. To address this question splenocytes from P14 TCR transgenic 
mice were adoptively transferred into a congenic C57BL/6 host, which was then 
subsequently infected with LCMV. Total RNA from P14 CD8+T cells was then 
isolated at days 0, 3, 6, 8, 10 and 14 post-LCMV infection (for day 3 total CD8+T 
cells were isolated). As shown in Figure V-1, I performed Q-PCR analysis with 
primers specific for Zbtb32 and found that ROG was induced in LCMV-specific 
CD8+T cells. As expected, ROG expression was minimal at early time points post 
infection but reached a peak around day 6 and then decreased during the course 
of the immune response. Interestingly, the pattern of ROG expression indicated 
that ROG is expressed in effector T cells and decreases during the memory 
phase of the T cell response. 
B. Increased CD8+T cell response and memory development in the ROG-               
deficient mice 
Since ROG was expressed in activated virus-specific CD8+T cells during 
an acute LCMV infection I questioned whether ROG was important in regulating 
in vivo CD8+T cell responses. To address this question, I used ROG-deficient 
mice (referred to as Zbtb32-/-) in which the coding regions (exons 2, 3, 4, 5, and a 
part of exon 6) of ROG were replaced with a neomycin resistance gene; these 
mice have been previously described (156). As reported previously, ROG-
deficient mice had a normal development with no apparent defects in maturation 
and total number of lymphocytes in the thymus, spleen and lymph nodes when 
compared to littermate control WT mice (data not shown). To test in vivo CD8+T 
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cell responses during an acute virus infection, I infected Zbtb32-/- and WT mice 
with LCMV, strain Armstrong. As shown in Figure V-2, the first apparent defect I 
found was that at day 8 and 15 post infection ROG-deficient mice had an 
enlarged spleen size compared to WT controls. Using Class-I MHC tetramers for 
immunodominant LCMV epitopes NP396 and GP33, I enumerated the absolute 
number and proportion of LCMV-specific CD8+T cells at days 6, 8 (peak of 
response) and 45 (memory phase) post infection. As shown in Figure V-3 and 4, 
I found that ROG-deficient mice had a higher proportion and absolute number of 
LCMV-specific CD8+T cells at day 8 post infection and these differences were 
maintained as long as day 45 post infection. To further confirm these results 
LCMV-specific CD8+T cells were identified by their ability to produce IFNγ in 
response to ex-vivo stimulation with LCMV NP396 and GP33 peptides. I found 
that at days 8 and 45 post infection a higher proportion of IFNγ-producing LCMV-
specific CD8+T cells were present in the ROG deficient mice when compared to 
WT controls (Figure V-5). These results indicate that ROG deficiency led to 
generation of an increased magnitude of a T cell response, which persisted into 
the memory phase, suggesting that ROG functions to negatively regulate the 
CD8+T cell response. The ability of virus-specific CD8+T cells to produce multiple 
cytokines, such as IFNγ, TNF and IL-2, simultaneously during viral infection is a 
primary indicator of their functional capacity, and  IL-2-producing CD8+T cells are     
more likely to become memory cells than those that do not make IL-2 (79). LCMV-
infected splenocytes from WT or ROG-deficient mice were cultured directly ex-  
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vivo for 5 hours in the presence of LCMV-specific GP33 and NP396 peptide 
epitopes. As shown in Figure V-6, at days 8 and 45 post infection, virus-specific 
CD8+T cells from Zbtb32-/- mice were enriched in IFNγ, TNF and IL-2 triple 
producers as compared to the WT controls (% indicated on top right represent 
triple cytokine producers), indicating that ROG-deficient T cells were functionally 
superior than their WT counterparts during the peak and memory phase of the 
immune response. Overall these results indicate that ROG would normally 
function to suppress T cell responses and memory development during acute 
viral infection. 
Increased magnitude of CD8+T cell response in Zbtb32-/- mice during an 
acute LCMV infection could have been due to defective viral clearance. 
Therefore, I enumerated viral-titers in Zbtb32-/- by plaque assay at days 4 and 8 
post-LCMV infection. As shown in Figure V-7, viral clearance in the spleen of 
Zbtb32-/- mice was similar to WT controls, indicating that the increased 
magnitude of the CD8+T cell response to LCMV in Zbtb32-/- mice was not due to 
impaired viral clearance. 
C. Increased CD8+T cell response in the ROG-deficient mice during 
Vaccinia virus infection 
Since I saw increased T cell responses in the ROG deficient mice during 
acute LCMV infection, I wanted to test whether ROG would function similarly in 
regulating T cell responses in an acute Vaccinia virus (VACV) infection. VACV is 
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a large DNA virus of the Poxviridae family, and infection with VACV can induce a 
potent primary CD8+T cell response and long term memory (197). I infected WT or 
ROG-deficient mice with VACV, strain WR, and enumerated the proportion and 
absolute number of VACV-specific CD8+T cells at days 7 and 14 post infection. 
VACV-infected splenocytes from WT or ROG-deficient mice were cultured 
directly ex-vivo for 5 hours in the presence of VACV-specific B8R and K3L 
peptide epitopes. As shown in Figure V-8 and 9, at days 7 and 14 post infection, 
a higher proportion and absolute number of IFNγ+ virus-specific CD8+T cells 
were present in the Zbtb32-/- mice compared to the WT controls. Therefore, I 
could show that ROG functions to negatively regulate CD8+T cell response in at 
least two different acute infection models. 
D. ROG intrinsically regulates CD8+T cell response and memory 
development 
For my studies I was using ROG-deficient mice in which Zbtb32 was 
ablated in both lymphoid and non-lymphoid cells. Therefore, absence of ROG in 
other cell types could have contributed to the increased CD8+T cell responses  
seen in the ROG-deficient mice. To test whether ROG intrinsically regulates 
LCMV-specific CD8+T cell responses I generated ROG-deficient P14 TCR 
transgenic mice. I adoptively transferred ROG-deficient and WT P14 TCR 
transgenic splenocytes into congenic C57BL/6 host, which were then 
subsequently infected with LCMV. The proportion and absolute number of 
Zbtb32-/- and WT P14 CD8+T cell responses were enumerated at days 6, 9 and 
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15 post-LCMV infection. As shown in Figure V-10, a higher proportion and 
absolute number of Zbtb32-/- P14 CD8+T cells accumulated in the congenic host 
compared to WT controls at days 9 and 15 post infection indicating that ROG 
intrinsically regulated CD8+T cell response during acute LCMV infection.  
         Recent studies have demonstrated that CD25 expression during the early 
expansion phase of the anti-viral CD8+T cell response is critical in regulating cell 
fate in that CD25hi cells become short-lived effector cells (80, 91). As shown in 
Figure V-11, a lower proportion of Zbtb32-/- P14 CD8+T cells expressed CD25 
when compared to WT controls at day 6 post-LCMV infection, indicating that 
Zbtb32-/- P14 CD8+T might preferentially become memory T cells. Surface 
expression of antigenic markers such as IL-7Rα along with KLRG-1 (MPEC: IL-
7Rhi KLRG-1lo) as well as CD27 and CXCR3 have been used to identify cells 
which will preferentially make it into memory (88). Moreover, expression of CD62L 
has been used to identify central memory T cells (Tcm) which are thought to 
mediate long term protection to secondary challenge (198). To address whether 
ROG intrinsically regulates generation of memory CD8+T cells, ROG-deficient  
and WT P14 TCR transgenic splenocytes were adoptively transferred into 
congenic C57BL/6 host, which were then subsequently infected with LCMV. At 
day 9 post-LCMV infection a higher proportion of P14+ Zbtb32-/- cells expressed 
the memory markers CD27 and CXCR3 when compared to WT control cells and 
no differences were observed in expression of IL-7R vs KLRG-1 and CD62L 
(Figure V-12). However, as shown in Figure V-13, by day 15 post-LCMV infection 
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I found that P14+ Zbtb32-/- CD8+T cells were enriched in memory precursor 
effector cells (IL-7Rhi KLRG-1lo) and expressed the memory markers CD27, 
CXCR3 and CD62L. The ability of CD8+T cells to produce multiple cytokines, 
such as IFNγ, TNF and IL-2 is an indicator of their functional capacity. As shown 
in Figure V-14, I found that a higher proportion of P14+ Zbtb32-/- CD8+T cells 
produced triple cytokines when compared to WT controls at day 9 and 15 post 
infection (% indicated on top right represent triple cytokine producers) in 
response to ex-vivo LCMV-GP33 peptide stimulation. The transcription factor 
EOMES promotes persistence of memory CD8+T cells (110). Since, a higher 
proportion of ROG-deficient T cells had a memory phenotype I compared 
EOMES expression in adoptively transferred P14 TCR transgenic Zbtb32-/- and 
WT CD8+T cells. As shown in Figure V-15, I found that a higher proportion of 
LCMV-specific P14+ CD8+T cells from Zbtb32-/- expressed EOMES compared to 
WT controls at day 9 post infection. The expression level of EOMES was also 
higher in Zbtb32-/- P14+CD8+T cells when compared to WT controls, as shown by 
the MFI in Figure V-15. Overall, the data suggests that ROG intrinsically 
negatively affects the magnitude of CD8+T cell response and suppresses the 
generation of memory precursor cells. 
E. ROG deficiency leads to generation of functionally superior memory 
CD8+T cells 
So far I have shown that ROG deficiency led to generation of CD8+T cells, 
which have a memory precursor phenotype. I questioned whether the difference 
 
 165 
 
 
 166 
 
 167 
in CD8+T cell phenotype between WT and ROG-deficient T cells was restricted to 
early time points or whether it is maintained into the memory phase of the 
immune response. I adoptively transferred ROG-deficient and WT P14 TCR 
transgenic splenocytes into congenic C57BL/6 host, which were then 
subsequently infected with LCMV. At day 30 post infection (memory phase), I 
found approximately a three-fold higher proportion and absolute number of 
Zbtb32-/- P14+CD8+T in the congenic host when compared to WT controls (Figure 
V-16). Furthermore, as shown in Figure V-17 a higher proportion of P14+ Zbtb32-
/- CD8+T cells represented functional memory and produced triple cytokines IFNγ, 
TNF and IL-2  (% indicated on top right represent triple cytokine producers) when 
compared to WT controls in response to ex-vivo LCMV-GP33 peptide 
stimulation.  
ROG-deficient memory CD8+T cells were enriched in IL-2 producers, 
which can be used as predictor of recall efficacy of a T cell. Therefore, I  
questioned whether ROG deficiency led to generation of bona fide superior 
memory T cells which had a better recall efficacy compared to WT controls. As 
shown in the schematic in Figure V-18, Zbtb32-/- or WT P14 CD8+T cells were 
sorted at day 30 post-LCMV infection and adoptively transferred into naïve hosts, 
which were then infected with LCMV. At day 5 post-infection I enumerated the 
proportion and absolute number of Zbtb32-/- or WT P14 CD8+T which were 
responding to a secondary LCMV challenge. As shown in Figure V-18, a higher 
proportion and absolute number of Zbtb32-/- P14 CD8+T cells were present in the 
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host when compared to WT controls. Therefore, the data show that intrinsic 
deficiency of ROG in CD8+T cells leads to generation of functionally superior 
memory T cells.  
F. Increased immunopathology and decreased survival of ROG-deficient 
mice in response to high dose LCMV Clone 13 infection 
LCMV-variant Clone 13 has been widely used to study T cell responses 
during persistent infection (11). Due to higher affinity of the viral glycoprotein for 
its α-dystroglycan receptor expressed on macrophages and dendritic cells Clone 
13 can systemically spread and replicate in both lymphoid and non-lymphoid 
tissues to cause persistent infection as opposed to the parent Armstrong strain 
which replicates in lymphoid tissues and fails to exhaust the T cell response (11). 
As shown in Figure V-19, in C57BL/6 mice the outcome of the LCMV Clone 13 
infection depends on the dose of viral inoculum. At low dose inoculum a strong T  
cell response is generated and virus is cleared, on the other end of the spectrum 
a high dose inoculum causes systemic viral replication leading to T cell 
exhaustion and persistent infection. Interestingly, in a medium dose response 
there is systemic viral replication along with strong T cell responses, which are 
detrimental to the host leading to immunopathology and host mortality (22).  
ROG deficient mice generated stronger T cell responses during acute 
LCMV infection compared to WT controls (Figure V-4). I hypothesized that a 
strong T cell response to high dose Clone 13 infection by ROG-deficient mice 
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might emulate a medium dose response leading to immunopathology and host 
mortality. To test the hypothesis, WT or Zbtb32-/- mice were intravenously 
injected with high dose inoculum of LCMV Clone 13. Consistent with the 
hypothesis, I found that between days 9 and 15 post infection approximately 70% 
of the ROG-deficient mice succumbed to the high dose Clone 13 infection 
(Figure V-20). Importantly, the kinetics of the death curve coincided with the peak 
of the T cell response suggesting that the mortality was T cell dependent. As 
shown in Figure V-21, there was also a precipitous drop in body weight of the 
ROG deficient mice around day 8 post infection, correlating with their decreased 
survival compared to WT controls.  Previous studies in our lab have shown that 
mortality during high dose LCMV Clone 13 infection can be associated with 
increased lung pathology (22). To test whether these ROG-deficient mice had 
increased lung pathology, lung sections from day 10 LCMV Clone 13 infected 
ROG-deficient and WT mice were stained with hematoxylin and eosin (H&E). In a     
blind study, Dr. Liisa Selin at UMMS scored the lung histology on an arbitrary 
scale from 1-5 (1 being the best and 5 being the worst). As shown in Figure V-22, 
compared to the WT mice, lungs of ROG-deficient mice had severe pulmonary 
oedema, interstitial mononuclear infiltration, and presence of bronchus 
associated lymphoid tissue (BALT) and necrotizing bronchiolitis. In accordance 
with this observation the lung histology scores of ROG deficient mice were much 
worse when compared to WT controls (Figure V-22). Since the kinetics of death 
seen in the ROG-deficient mice suggested that mortality was T cell dependent, I 
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questioned whether ROG-deficient mice were generating a stronger T cell 
response to Clone 13 infection. To address this question, splenocytes and lung 
leukocytes were cultured directly ex-vivo for 5 hours in the presence of LCMV 
peptide epitopes NP396 and GP33. As detected by IFNγ production in response 
to cognate peptide, approximately twice as many NP396- and GP33-specific 
CD8+T cells were present in the spleen and lungs of Zbtb32-/- mice at day 10 post 
infection when compared to WT controls (Figure V-23). A stronger CD8+T cell 
response might also lead to enhanced viral clearance and to test this idea I 
enumerated LCMV Clone 13 viral-titers in the spleen and liver of Zbtb32-/- and 
WT mice at day 10 post infection. As shown in Figure V-24, viral clearance in the 
spleen of Zbtb32-/- mice was enhanced compared to WT controls, though no 
significant differences were observed in the liver. Overall the data suggest that 
higher frequencies of IFNγ producing virus-specific CD8+T cells in Zbtb32-/- mice 
also resulted in enhanced viral control following LCMV Clone 13 infection. 
However, systemic viral replication along with strong T cell responses in the 
ROG-deficient mice led to lung immunopathology and increased host mortality. 
G. Discussion to Chapter V. 
Transcription factors of the POZ family of proteins have been shown to 
play a role in T cell function and differentiation. This study was performed in 
collaboration with Dr. HyunMu Shin and Dr. Leslie J. Berg at UMMS. In this 
chapter I have shown that the transcription factor ROG plays a non-redundant 
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role in regulating T cell responses and memory generation during acute and 
chronic LCMV infection. 
 Initial studies done by Dr. HyunMu Shin had shown that ROG was 
induced by IL-2 signaling. A recently published study showed by ChIP-seq 
analysis that ROG is a direct target of STAT5 (199), consistent with our data that 
ROG is an IL-2 induced gene. Furthermore, by performing Q-PCR analysis to 
quantitate Zbtb32 mRNA we found that IFNβ and IL-12 can also induce ROG in 
addition to IL-2 (data not shown). IL-2, IFNβ and IL-12 cytokines are induced 
early during an anti-viral response, consistent with the idea of ROG being an 
early induced gene. 
In this study I have shown that ROG deficiency in CD8+T cells leads to an 
increased magnitude of CD8+T cell response. This could have been due to 
increased proliferation or decreased apoptosis of ROG-deficient T cells. I did not 
find any differences in active Caspase-3 staining between WT and Zbtb32-/- P14 
CD8+T cells at day 9 and day 15 post-LCMV infection (data not shown). 
Therefore, differences in T cell apoptosis do not account for increased proportion 
and absolute number of ROG-deficient T cells. To test whether ROG deficiency 
leads to increased T cell proliferation in vivo, I compared BrdU incorporation 
between day 7 LCMV-infected P14 TCR transgenic Zbtb32-/- or WT CD8+T cells 
(data not shown). I did not find any differences in BrdU incorporation between 
WT or Zbtb32-/- P14 CD8+T cells suggesting that there were no differences in 
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their proliferative capacities at the time point which was tested. Previous studies 
have shown that ROG-deficient T cells are more proliferative in vitro (154, 156). 
BrdU labels cells which are actively proliferating and undergoing DNA synthesis 
and is not an indicator of the number of divisions a cell has gone through. 
Therefore, due to this limitation of the BrdU assay I cannot conclude that there 
were no differences in proliferation between WT and ROG-deficient CD8+T cells.  
In response to a high dose LCMV Clone 13 infection ROG-deficient mice 
generated stronger T cell responses and had enhanced viral clearance 
compared to WT mice. However, I also saw increased lung pathology and 
mortality in the ROG-deficient mice. Since ROG-deficient mice had stronger T 
cell responses during LCMV Clone 13 infection, I questioned whether the 
pathology was CD4+T cell dependent. I found no differences in survival of LCMV 
Clone 13 infected ROG-deficient mice in which CD4+T cells had been depleted 
by an antibody treatment when compared to control-treated mice (data not 
shown), suggesting that CD4+T cells did not contribute to the pathology. Though 
we have not directly tested, the immunopathology seen in ROG-deficient mice 
during persistent LCMV infection could be directly due to the increased perforin 
cytotoxicity or inflammatory cytokines being produced by CD8+T cells and 
potentially other cell types. 
To further elucidate the downstream mechanism by which ROG regulates 
CD8+T cell responses, microarray analysis was done to compare gene 
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expression profiles in WT or Zbtb32-/- P14 CD8+T cells at day 6 and day 8 post-
LCMV infection. Surprisingly, very few genes with a known function were found 
to be differentially regulated between Zbtb32-/- and WT P14 CD8+T cells at day 6 
post-infection (Table V-1) and similar results were obtained at day 8 post-
infection (data not shown). PVR/CD155 (polio virus receptor) is a member of the 
nectin family and is known to interact with activating T and NK cell receptor 
CD226 (200). The co-stimulatory CD155-CD226 axis is known to regulate pro-
inflammatory balance in humans (201), and CD155 was shown to induce 
increased proliferation in Ras mutated cells (202). Consistent with our microarray 
analysis I found that CD155 was upregulated at the protein level on Zbtb32-/- P14 
CD8+T at day 6 post-LCMV infection compared to WT controls (data not shown). 
Dr. HyunMu Shin also found CD7 mRNA to be upregulated on Zbtb32-/- T cells 
compared to WT controls, and expression of CD7 on human CD8+T cells has 
been shown to correlate with memory subsets (203). The transcription factor  
EOMES promotes persistence of memory CD8+T cells (110). EOMES was not 
differentially expressed between Zbtb32-/- and WT T cells in our microarray 
analysis, but, at the protein level higher proportion of EOMES-expressing CD8+T 
cells were present in the ROG-deficient mice at day 8 (Figure V-15) and day 15 
(data not shown) post-LCMV infection. Our microarray analysis has revealed 
some potentially interesting downstream targets of ROG, and if any of these 
genes contribute to the ROG phenotype and are directly regulated by ROG 
remains to be tested. 
 
 183 
 
 
 184 
Overall in the studies highlighted in this chapter I show that ROG plays a 
non-redundant role in regulating CD8+T cell response during acute and chronic 
viral infections. Interestingly, ROG deficiency was beneficial to the host in an 
acute infection setting and led to generation of a stronger T cell response and 
better memory population compared to WT controls. Contrary to an acute 
infection setting, ROG deficiency during a chronic LCMV infection led to 
immunopathology and host mortality. Therefore these studies highlight a unique 
system where deficiency of a transcription factor can have both beneficial and 
detrimental effects depending on the infection model used (Figure V-25). 
Furthermore, it also highlights the importance of carefully considering the effects 
of modulating the transcriptional machinery to regulate the balance between 
effector and memory T cell generation during different infections, as it might lead 
to different potential outcomes. 
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CHAPTER VI: DISCUSSION 
For a successful immune response, it is essential that T cells eradicate the 
pathogen and form a population of long-lived memory T cells to prevent re-
infection by the same pathogen. During an immune response the effector CD8+T 
cell pool is heterogeneous, and comprises of short-lived effector cells and 
memory precursor cells. Several surface antigenic markers can be used to 
identify T cells with a memory potential (68), but we are only beginning to 
elucidate the mechanisms underlying transcriptional regulation of effector-
memory CD8+T cell differentiation (68). Understanding the mechanisms that 
govern memory CD8+T cell differentiation and maintenance is essential to aid 
both preventative and therapeutic vaccine designs. 
T cells activated in the secondary lymphoid organs migrate to non-
lymphoid tissues to eliminate the foreign antigen (50, 128-130, 204). Since most of 
the infections are initiated in the non-lymphoid tissues, the presence of memory T 
cells in the peripheral non-lymphoid tissues is critical for protective immunity 
during secondary infections (133, 137, 138). Our lab has previously shown that 
during and after resolution of the immune response, LCMV-specific CD8+T cells 
in the non-lymphoid tissues are more resistant to apoptosis than those in the 
lymphoid organs (139). Understanding the mechanisms which regulate T cell 
survival in non-lymphoid tissue environments is important, as this stability of T 
cells in the peripheral tissues bolsters protective immunity to secondary 
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infections. This thesis specifically studies mechanisms regulating survival of T 
cells in non-lymphoid tissues and transcription-factor mediated regulation of 
effector-memory T cell generation. 
In chapter III, I have examined the factors contributing to decreased T cell 
apoptosis in the non-lymphoid tissues. As a representative of non-lymphoid 
tissue, I have primarily looked at the peritoneal cavity, which is also the site of 
antigen delivery in my experiments. The development of immune responses and 
dynamics of T cell migration into the peritoneal environment are not fully 
understood. The peritoneal cavity is unique from other non-lymphoid tissues as it 
lacks a defined architecture and comprises of peritoneum wall, omentum, 
mesentery and free cells present in the peritoneal fluid. Although not considered 
as a true secondary lymphoid organ, the milky spots consists of lymphocytes 
embedded in the omentum and can drive T and B cell responses in response to 
peritoneal antigens (205). Omentum was also shown to be a site for generation of 
NK and T cell dependent anti-tumor response following delivery of tumor cells to 
the peritoneal cavity (206). However, one study identified mediastinal lymph 
nodes as a primary site for initial T cell responses to antigens delivered into the 
peritoneal cavity (207). Since the kinetics of T cell response in the mediastinal 
lymph nodes are faster when compared to other lymphoid and non-lymphoid 
tissues during an immune response to intra-peritoneally delivered LCMV (207), I 
chose not to look at mediastinal lymph nodes while comparing tissue-dependent 
T cell apoptosis in my studies. Several studies have shown that following 
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activation in the secondary lymphoid organs T cells need to express appropriate 
chemokine receptors or integrins to gain entry into the non-lymphoid tissues 
(208). For instance, migration into the small intestine epithelium requires 
expression of CCR9 and α4β7 integrin (209), whereas migration to the skin 
requires expression of cutaneous lymphocyte antigen (CLA) (210). T cell 
recruitment to the peritoneum can be mediated by P and E selectins (211), and in 
this thesis I have shown that CXCR3 may play a role in driving T cell migration 
into the peritoneal cavity. 
 Recent studies have identified a subset of cells called the resident 
memory T cells (Trm), which specifically reside and persist in the non-lymphoid 
tissues without recirculating (212-215). Trm cells express CD103 and CD69, and 
are maintained by action of the cytokines TGFβ and IL-15 (213, 215). Our lab has 
previously shown that TGFβ may be one of the factors promoting T cell survival 
in the peritoneal environment (139). Furthermore, I have found that virus-specific 
CD8+T cells in the PEC have increased expression of CD122 (Figure III-34), 
which may allow for IL-15 mediated T cell survival. Peritoneal cavity is 
considered an ‘effector permissive’ tissue, as it is accessible to effector T cells 
during an immune response after which it becomes inaccessible to circulating 
memory T cells (208, 216). Parabiosis experiments have shown that non-lymphoid 
tissues can differ in their permissiveness to memory T cells (210). Unlike lungs 
and liver, the entry into peritoneal cavity, brain and lamnia propria by memory T 
cells is restricted (210). Thus it is possible that majority of the memory T cells in 
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the peritoneal cavity would be generated from the effector T cells which are 
seeded during the primary immune response. Therefore, as elucidated in this 
thesis, factors promoting survival of T cells in the peritoneal cavity during 
resolution of the immune response will be critical in ensuring maintenance and 
survival of appropriate numbers of functional memory T cells to provide 
protection to secondary challenges. Furthermore, analogous mechanisms might 
also regulate T cell survival and memory development in other restricted non-
lymphoid tissues.   
Similar transcriptional programs might regulate generation and survival of 
memory T cells in the lymphoid and non-lymphoid tissues. Consistent with this 
idea, I have several lines of preliminary evidence indicating that differential 
expression of Blimp-1 might contribute to tissue-dependent apoptotic differences: 
a) in a single experiment I found that decreased proportions of Blimp-1-
expressing LCMV-specific GP33+CD8+T cells were present in the PEC compared 
to spleen at day 10 (49±4.1% in the PEC vs 66.3±3.3% in the spleen) and day 15 
(32.3±3.3% in the PEC vs 59.1±4.8% in the spleen) post-LCMV infection, b) 
microarray analysis comparing virus-specific CD8+T cells in the PEC and spleen 
at day 9 post-LCMV infection revealed a 2 fold up-regulation of Blimp-1 message 
in the spleen compared to the PEC, c) higher proportions of CD27 expressing T 
cells were present in the PEC compared to spleen (Figure III-9), and we have 
identified CD27 as a Blimp-1 regulated gene in chapter IV, d) approximately 
100% of virus-specific Blimp-1-deficient T cells were found to be expressing 
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TCF-1 at day 8 post-LCMV infection (data not shown), suggesting that Blimp-1 
might be a master regulator of TCF-1, and I have shown that TCF-1 is important 
in promoting survival of T cells in the non-lymphoid tissues during resolution of 
the immune response (Figure III-20), e) decreased Blimp-1 expression in the 
PEC further supports the idea of increased IL-2 being produced in the PEC, 
since Blimp-1 is known to suppress IL-2 production in T cells (193). Future studies 
will need to address whether differential expression of Blimp-1 might also 
contribute to tissue dependent apoptotic differences. 
The studies highlighted in chapter IV, clearly demonstrate that Blimp-1 
negatively regulates CD25 (IL-2Rα) and CD27 expression to impact the balance 
of short-lived and memory precursor effector CD8+T cells responding to an acute 
virus challenge. One of the important findings of this study is the differential 
function of IL-2Rα signaling at T cell priming and contraction. IL-2Rα signaling 
during T cell priming promotes generation of short-lived effectors (80, 91), but 
during the peak and resolution of the immune response IL-2Rα signals promote 
generation of memory precursors, and this change is dependent on Blimp-1. In 
accordance with our results, timing of IL-2 therapy delivered in form of IL-2 
complexes to IL-2-deficient CD4+T cells during priming phase of the immune 
response to Influenza virus infection leads to generation of effector-like CD4+T 
cells, whereas IL-2 therapy during peak of the response promotes generation of 
memory like CD4+T cells (unpublished observation, personal communication Dr. 
Kai Mckinstry and Dr. Tara Strutt). Interestingly, Blimp-1 is itself an IL-2-induced 
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gene and, in an auto-regulatory feedback loop, shuts down IL-2 production to 
regulate the effector T cell pool (193). Genome wide ChIP-sequencing analysis 
done by our collaborating group revealed a large number Blimp-1 target genes 
and these studies will provide a starting ground to identify other mechanisms by 
which Blimp-1 suppresses memory CD8+T cell differentiation. 
In the studies presented in Chapter V, I have shown that the transcription 
factor ROG negatively regulates CD8+T cell responses and memory generation 
during viral infections. In collaboration with Dr. HyunMu Shin and Dr. Leslie J. 
Berg we are trying to elucidate upstream and downstream mechanisms by which 
ROG regulates in vivo T cell responses. Similar to Blimp-1, we found that ROG is 
an IL-2 induced gene. A recent study showed that ROG is a STAT5 target gene 
(199), consistent with ROG being an IL-2 regulated gene. Interestingly, in B cells 
ROG was shown to negatively regulate CIITA and MHC-II gene expression (157), 
a process also regulated by Blimp-1. Moreover, in this study Blimp-1 was shown 
to interact with ROG. Blimp-1 and ROG are transcriptional repressors, and both 
of them can suppress memory T cell generation as shown in Chapter IV and V. 
Therefore, it is possible that ROG and Blimp-1 might negatively regulate similar 
genes in T cells. Only a few genes were shown to be differentially regulated 
between WT and Zbtb32-/- T cells in our microarray analysis at day 6 and day 8 
post-LCMV infection (Table V-1). This could have been due to an overlapping 
function of ROG and Blimp-1 in T cells, as Blimp-1 is also expressed at high 
levels at these time points and Blimp-1 is still active in Zbtb32-/- T cells. However, 
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the T cell phenotype seen during ROG deficiency indicates that ROG also plays 
a non-redundant role in regulating in vivo T cell responses. It is tempting to 
speculate that Blimp-1 and ROG might co-operate to negatively regulate T cell 
responses and memory generation during viral infections. 
Recent studies based on kinetic analysis of gene expression changes in 
CD8+T cells during an immune response have revealed that a network of genes 
work in coordinated fashion to regulate CD8+T cell differentiation (127, 217). These 
studies show that during an immune response transcription factors can regulate 
a large cluster of genes which are induced or suppressed in a concerted fashion 
and their kinetic regulation can give us insights into the biological process they 
control. In those studies Blimp-1 was shown to be in a cluster of genes which 
regulate effector-memory differentiation (127), and our studies have revealed that 
Blimp-1 can directly negatively regulate a number of transcription factors known 
to be associated with memory CD8+T cell differentiation (81). Analysis of 
transcriptional networks did not identify ROG as one of the signature genes 
involved in effector-memory transition (127, 217). However, gene expression 
analysis of Zn finger containing transcription factors during both acute and 
chronic LCMV infection (89) have shown that kinetics of ROG expression are 
similar to Blimp-1, although ROG expression declines much faster than Blimp-1 
once the immune response has resolved. Thus, the expression kinetics and 
function of ROG as presented in this thesis suggest that ROG might be a part of 
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the same cluster of genes as Blimp-1 and forms a part of a network to promote 
terminal effector fate in CD8+T cells.  
Understanding the dynamics which regulate the fate of a T cell on a single 
cell level might also help us gain insights into how transcriptional programs are 
imprinted during course of the immune response. Some elegant studies have 
been done to track the fate of individual CD8+T cell precursor during an infection 
(218-220). It was shown that diverse types of effector CD8+T cell progeny are 
generated from a single cell clone and inflammatory microenvironment and tissue 
specific factors can influence  this heterogeneity on a populational level (218). 
Interestingly, it has been shown that SLEC and MPEC populations reside in 
different areas in the spleen supporting the idea that microenvironment can 
influence T cell fate (221). SLECs localize to red pulp areas whereas MPECs 
localize to white pulp and T cell zones where they interact with stromal cells 
which produce IL-7. The studies highlighted in Chapter III show that tissue 
environment can also influence T cell fate and a higher proportion of T cells with 
an antigenic and transcription factor phenotype correlating with enhanced 
memory and survival were found in the non-lymphoid tissues when compared to 
lymphoid organs. Therefore, individual T cells can receive cues from the tissue 
microenvironment to induce an antigenic and transcriptional profile governing 
their fate.  
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For an optimal response, CD8+T cells require antigenic stimulation 
through the TCR, as well as co-stimulation and cytokine stimulation via 
inflammatory cytokines. The quantity and quality of these three signals inscript a 
transcriptional program governing the fate of effector T cells. It is now evident 
that several transcription factors act in concert to regulate the balance between 
short-lived effector and memory T cell generation. In this thesis we have 
identified one of the mechanism by which transcription factor Blimp-1 regulates 
the balance between effector and memory T cell generation. We also found that 
the transcription factor ROG negatively regulates CD8+T cell responses and 
memory development. Stability of memory T cells at non-lymphoid tissues may 
be critical for immunity to secondary challenges and we found that decreased T 
cell apoptosis in the non-lymphoid tissues was due to a combination of several 
factors. As shown in Figure VI-1, several pathways act in conjunction to restore 
homeostasis and promote development of memory T cells in lymphoid and non-
lymphoid tissues to provide protection to secondary challenges. This thesis will 
contribute to our understanding of the mechanisms promoting stability of T cells 
in non-lymphoid tissues and transcriptional regulation of memory CD8+T cell 
differentiation. The knowledge of these processes could eventually allow us to 
manipulate T cells and their environment to improve treatment for infectious 
diseases and generate better vaccine designs.  
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